

Publikationer NKBC 2009-2025

2025

Adwall L, Fredriksson I, Hultin H, Stålberg P, Mani M, Norlén O, Sackey H. Major systemic infection following breast cancer surgery associated with worse oncological outcomes. *Br J Surg*. 2025 Nov 29;112(12):znaf233. doi: 10.1093/bjs/znaf233.PMID: 41330723

Aine M, Nacer DF, Arbajian E, Veerla S, Karlsson A, Häkkinen J, Johansson HJ, Rosengren F, Vallon-Christersson J, Borg Å, Staaf J. The DNA methylation landscape of primary triple-negative breast cancer. *Nat Commun*. 2025 Mar 28;16(1):3041. doi: 10.1038/s41467-025-58158-x.PMID: 40155623

Albrecht J, Müller M, Hafstað V, Kaminska K, Vallon-Christersson J, Honeth G, Persson H. Dynamic methylation and expression of alternative promoters for oestrogen receptor alpha in cell line models of fulvestrant resistance. *Mol Oncol*. 2025 Jan;19(1):204-224.doi: 10.1002/1878-0261.13713. PMID: 39108022

Allen G, Heiland EG, Teleka S, Glimelius I, Michaëlsson K, Byberg L, Brooke HL. Association of change in physical activity with use of outpatient specialist care and hospitalisations among breast cancer survivors with type 2 diabetes in Sweden. *Br J Cancer*. 2025 Sep;133(5):655-664. doi: 10.1038/s41416-025-03099-x. Epub 2025 Jul 4.PMID: 40615717

Billaud A, Figlioli G, Mooser C, Casamassima I, Azzoni V, Srivatsa J, et al. Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer. *Breast*. 2025 Oct 30;85:104619. doi: 10.1016/j.breast.2025.104619. PMID: 41223770

Boman C, Tranchell C, Liu X, Eriksson Bergman L, Toli MA, Bergh J, Foukakis T, Matikas A. Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study. *J Natl Compr Canc Netw*. 2025 Mar 12;23(4):e247093. doi: 10.6004/jnccn.2024.7093.PMID: 40073831

Carreira H, Strongman H, Feychting M, Hubbert L, Hedayati E, Bidulka P, Matthews A, Bhaskaran K. Use of anthracyclines and trastuzumab for breast cancer in women with and without a history of cardiovascular disease in Sweden: a national cross-sectional study. *Cardiooncology*. 2025 Jun 20;11(1):56. doi: 10.1186/s40959-025-00356-z.PMID: 40542432

Cha YJ, O'Connell CE, Calhoun BC, Felsheim BM, Fernandez-Martinez A, Fan C, Brueffer C, Larsson C, Borg Å, Saal LH, Perou CM. Genomic Characteristics Related to Histology-based Immune Features in Breast Cancer. *Mod Pathol*. 2025 May;38(5):100736. doi: 10.1016/j.modpat.2025.100736. PMID: 39956271

Dembrower KE, Crippa A, Eklund M, Strand F. Human-AI Interaction in the ScreenTrustCAD Trial: Recall Proportion and Positive Predictive Value Related to Screening Mammograms Flagged by AI CAD versus a Human Reader. *Radiology*. 2025 Mar;314(3):e242566. doi: 10.1148/radiol.242566. PMID: 40100021

Du X, Gkekos L, Rai B, Johansson A, Fredriksson I, Rantalainen M, Heintz E, Hao S, Clements M. Breaking down the costs for breast cancer: Insights from Sweden's National Quality Register. *Breast*. 2025 Nov 11;85:104646. doi: 10.1016/j.breast.2025.104646. PMID: 41241975

Eriksson Bergman L, Matikas A, Liu X, Foukakis T. Adherence to adjuvant endocrine therapy including GnRH-analogues and survival: a population-based cohort study. *EClinicalMedicine*. 2025 Sep 12;88:103493. doi: 10.1016/j.eclinm.2025.103493 PMID:41181852

Ficorella L, Eriksson M, Czene K, Leslie G, Yang X, Carver T, Stokes AE, Easton DF, Hall P, Antoniou AC. Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model. *JCO Precis Oncol*. 2025 Sep;9:e2500203. doi: 10.1200/PO-25-00203. Epub 2025 Sep 26. PMID: 41004699

Ficorella L, Yang X, Mavaddat N, Carver T, Hassan H, Dennis J, et al. Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population. *Br J Cancer*. 2025 Oct;133(6):844-855. doi: 10.1038/s41416-025-03117-y. Epub 2025 Jul 17. PMID: 40676226

Hammarström M, Gabrielson M, Bergqvist J, Lundholm C, Crippa A, Bäcklund M, Wengström Y, Borgquist S, Eliasson E, Eriksson M, Tapia J, Czene K, Hall P. Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial. *J Natl Cancer Inst*. 2025 Apr 1;117(4):629-636. doi: 10.1093/jnci/djae280. PMID: 39514025

Hernström V, Josefsson V, Sartor H, Schmidt D, Larsson AM, Hofvind S, Andersson I, Rosso A, Hagberg O, Lång K. Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study. *Lancet Digit Health*. 2025 Feb 3:S2589-7500(24)00267-X. doi: 10.1016/S2589-7500(24)00267-X. PMID: 39904652

Ho PJ, Loo CKY, Lim RJY, Goh MH, Abubakar M, Ahearn TU, et al. Threshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women. *Cancers (Basel)*. 2025 Nov 3;17(21):3561. doi: 10.3390/cancers17213561 PMID: 41228354

Hohmann L, Nacer DF, Aine M, Memari Y, Black D, Bowden R, Davies HR, Borg Å, Vallon-Christersson J, Nik-Zainal S, Staaf J. Molecular profiling of the Basal-like intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer. *Genome Med*. 2025 Dec 1;17(1):146. doi: 10.1186/s13073-025-01576-9. PMID: 41327380

Hohmann L, Sigurjonsdottir K, Campos AB, Nacer DF, Veerla S, Rosengren F, Reddy PT, Häkkinen J, Nordborg N, Vallon-Christersson J, Memari Y, Black D, Bowden R, Davies HR, Borg Å, Nik-Zainal S, Staaf J. Genomic characterization of the HER2-enriched intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer. *Nat Commun*. 2025 Mar 5;16(1):2208. doi: 10.1038/s41467-025-57419-z. PMID: 40044693

Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, et al. Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer. *NPJ Breast Cancer*. 2025 Feb 19;11(1):18. doi: 10.1038/s41523-025-00733-y. PMID: 39971965

Illipse M, Gasparini A, Christoffersen B, Hall P, Czene K, Humphreys K. Studying the association between longitudinal nondense breast tissue measurements and the risk of breast cancer: a joint modeling approach. *Am J Epidemiol*. 2025 Apr 8;194(4):1065-1071. doi: 10.1093/aje/kwae196. PMID: 39004517

Inan El-Naggar A, Karakatsanis A, Valachis A. Real-world survival outcomes of neoadjuvant versus adjuvant chemotherapy in operable triple-negative breast cancer: a propensity score matched registry-based study. *Acta Oncol*. 2025 Oct 1;64:1334-1341. doi: 10.2340/1651-226X.2025.43990. PMID:41036550

Kimbung S, Veerla S, Muhammad K, Ehinger A, Vallon-Christersson J, Malmberg M, Loman N. Global transcriptional complexity of estrogen receptor-low positive breast cancers in the prospective Swedish population-based SCAN-B cohort. *Clin Cancer Res*. 2025 Jul 1;31(13):2695-2709. doi: 10.1158/1078-0432.CCR-24-3435. PMID: 40227228

Kouvaraki M, Zerdes I, Sifakis EG, Sarafidis M, Matikas A, Tzoras E, Kjällquist U, Stathopoulou K, Lövrot J, Alkodsí A, Hartman J, Sotiriou C, Richard F, Hatschek T, Herold N, Bergh J, Rassidakis GZ, Foukakis T. Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer. *Int J Cancer*. 2025 Apr 15;156(8):1621-1633. doi: 10.1002/ijc.35319. PMID: 39729390

Kramer CJH, van Wijk LM, Ruano D, Gelpke-Vermeulen S, van der Tuin K, van der Stoep N, van Wezel T, Wesseling J, Vallon-Christersson J, Smit VTHBM, Cohen D, Vrieling H, Staaf J, Bosse T, van Asperen CJ, Vreeswijk MPG. Capturing breast cancers' copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond. *Br J Cancer*. 2025 Nov;133(8):1199-1207. doi: 10.1038/s41416-025-03134-x. PMID: 40849357

Le Cornet C, Jung AY, Behrens S, Middha P, Truong T, Jernström H, et al. Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer. *JAMA Netw Open*. 2025 Jul 1;8(7):e2519236. doi: 10.1001/jamanetworkopen.2025.19236. PMID: 40622713

Liu X, Eriksson Bergman L, Boman C, Foukakis T, Matikas A. Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: A population-based study. *Eur J Surg Oncol*. 2025 Jan 7:109587. doi: 10.1016/j.ejso.2025.109587. PMID: 39794172

Liu X, Binicy B, Acs B, Eriksson Bergman L, Loibl S, Gnant M, Untch M, Valachis A, Bergh J, Hartman J et al. Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study. *Lancet Reg Health Eur*. 2025 Sep 29;59:101471. doi: 10.1016/j.lanepe.2025.101471. eCollection 2025 Dec. PMID: 41080912

Lundgren C, Engvall K, Fredriksson I, Valachis A. Short-term mortality in older (≥ 70 years) patients with early breast cancer treated with neo-/adjuvant chemotherapy - a Swedish nationwide retrospective population-based study. *J Geriatr Oncol* 2025 Mar;16: 102220. <https://doi.org/10.1016/j.jgo.2025.102220>. Epub 2025 Mar 13. PMID: 40086025

Ma Z, He W, Zhang Y, Mao X, Tapia J, Hall P, Humphreys K, Czene K. First mammography screening participation and breast cancer incidence and mortality in the subsequent 25 years:

population based cohort study. *BMJ*. 2025 Sep 24;390:e085029. doi: 10.1136/bmj-2025-085029.PMID: 40992899

Mao X, He W, Tapia J, Holowko N, Bergqvist J, Humphreys K and Czene K. Screen-Detected Breast Cancer Outcomes by Mammography Participation Immediate Past Screening. *JAMA Netw Open*. 2025 Oct 1;8(10):e2535330. doi: 10.1001/jamanetworkopen.2025.35330. PMID: 41042510

Mallios P, Manshadi MD, Hubbert L, Aydin T, Maes C, Rantala J, Liljegren A, Kiani NA, Hedayati E. Cardiovascular health in breast cancer patients: insight on BRCA1/2 mutations impact. *Cardiooncology*. 2025 Jan 21;11(1):5. doi: 10.1186/s40959-025-00302z. PMID: 39838506

Nyqvist-Streng J, Helou M, Helou K, Chamalidou C, Kovács A, Parris TZ. The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study. *Breast Cancer Res Treat*. 2025 Jan 12. doi: 10.1007/s10549-025-07610-z. PMID: 39799529

Nyqvist-Streng J, Somi J, Martikainen J, Olsson M, Helou K, Chamalidou C, Kovács A, Parris TZ. Age and comorbidity in relation to treatment and survival outcomes in triple-negative breast cancer: A Swedish nationwide registry-based study. *J Geriatr Oncol*. 2025 May 7;16(5):102255. doi: 10.1016/j.jgo.2025.102255. PMID: 40339509

Nyqvist-Streng J, Helou M, Helou K, Chamalidou C, Kovács A, Parris TZ. The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in triple-negative breast cancer: A Swedish nationwide registry-based study. *Breast Cancer Res Treat* 2025 Apr;210(3):719-736. PMID: 39799529

Richter C, Dethlefsen O, Axelsson U, Lundberg K, Rydén L, Johnsson P, Ringdahl U, Hallberg IR, Borrebaeck CAK. Multilayered Epigenetic Analysis Identifies a Molecular Portrait for Psychological Resilience in Patients With Breast Cancer. *Biol Psychiatry Glob Open Sci*. 2025 Jun 3;5(5):100545. doi: 10.1016/j.bpsgos.2025.100545. eCollection 2025 Sep. PMID: 40697488

Roostee S, Killander F, Saghir H, Nacer DF, Häkkinen J, Sasiain I, Veerla S, Vallon-Christersson J, Loman N, Ohlsson M, Staaf J. Stand-alone transcriptional immune response prediction in primary triple-negative breast cancer. *Cancer Res Commun*. 2025 Dec 1;5(12):2157-2174. doi: 10.1158/2767-9764.CRC-25-0453. PMID: 412121151

Sartor H, Hagberg O, Hemmingsson O, Lång K, Wadsten C. Breast cancer recurrence in relation to mode of detection: implications on personalized surveillance. *Breast Cancer Res Treat*. 2025 Jan;209(1):85-92. doi: 10.1007/s10549-024-07475-8. Epub 2024 Sep 10. PMID: 39251456

Steen S, Karlsson E, Björnheden I, Rask G, Thurffjell V, Nobin H, Kolodziej B, Bodén A, Bauer A, Einefors R, Nilsson P, Zerdes I, Papakonstantinou A, Foukakis T, Fredriksson I, Rantalainen M, Colón-Cervantes E, Kovacs A, Acs B*, Hartman J*. Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs. ER-zero breast cancer: a Swedish population-based cohort study. *Breast Cancer Res*. 2025 Nov 29;27(1):213. doi: 10.1186/s13058-025-02179-3. PMID: 41316480

Suger AH, Chen H, Haas CB, Fan S, Scott CG, Bolla MK, et al. Interactions Between Genetic and Epidemiological Factors Influencing Mammographic Density. *Am J Epidemiol*. 2025 Mar 27;kwaf067. doi: 10.1093/aje/kwaf067. PMID: 40153356

Svensson M, Bendahl PO, Alkner S, Hansson E, Rydén L, Dihge L. Development and validation of prediction models for sentinel lymph node status indicating postmastectomy radiotherapy in **breast cancer**: population-based study. *BJs Open*. 2025 Mar 4;9(2):zraf047. doi: 10.1093/bjsopen/zraf047.PMID: 40197824

Thorén T, Lindh JD, Molden E, Kristiansen Kringen M, Bergh J, Eliasson E, Margolin S. CYP2D6 genotype and outcome in tamoxifen treated early breast cancer. *Acta Oncol*. 2025 Jul 2;64:848-856. doi: 10.2340/1651-226X.2025.43208. PMID: 40600576

Thurell J, Doppelbauer L, Verheul EM, Petrov I, Karsten MM, Koppert LB, Bergh J, Fredriksson I, Lindgren P, Kiani N, Hedayati E. Benchmarking cancer outcomes in Europe: a scoping review of methodologies and case-mix adjustments. *ESMO Real World Data and Digital Oncology* 2025: Sept 3;100176. doi: 10.1016/j.esmorw.2025.100176.

Toli MA, Liu X, Massa D, Lando S, Boman C, Tsiknakis N, Tranchell C, Papakonstantinou A, Fotia G, Vernieri C et al. Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study. *Lancet Reg Health Eur*. 2025 Sep 2;58:101432. doi: 10.1016/j.lanepe.2025.101432. PMID: 40980814

Tzikas AK, Holmberg E, Parris TZ, Kovács A, Lovmar L, Karlsson P. Survival outcomes in hormone receptor-negative breast cancer among BRCA carriers versus noncarriers in western Sweden. *Acta Oncol*. 2025 Apr 16;64:550-557. doi: 10.2340/1651-226X.2025.43109. PMID: 40235390

van Dam P, Tomatis M, Ponti A, Marotti L, Verhaegen J, Aristei C, Cardoso MJ, Cheung KL, Curigliano G, De Vries J, Santini D, Sardanelli F, Rubio IT; Eusoma Working group. Locally advanced breast cancers: the EUSOMA experience. *Eur J Surg Oncol*. 2025 Nov 25:111303. doi: 10.1016/j.ejso.2025.111303. Epub ahead of print. PMID: 41391957

Zanti M, O'Mahony DG, Parsons MT, Dorling L, Dennis J, Boddicker NJ, et al. Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification. *Nat Commun*. 2025 May 25;16(1):4852. doi: 10.1038/s41467-025-59979-6.PMID: 40413188

Zhang Y, Rodriguez J, Mao X, Grassmann F, Tapia J, Eriksson M, Hall P, Czene K. Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer. *JAMA Oncol*. 2025 May 1;11(5):519-527. doi: 10.1001/jamaoncol.2025.0167. PMID: 40146116

2024

Acs B, Hartman J, Sönmez D, Lindman H, Johansson ALV, Fredriksson I. Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study. *Lancet Reg*

Health Eur. 2024 Mar 19;40:100886. doi: 10.1016/j.lanepe.2024.100886. eCollection 2024 May. PMID: 38745990

Advall L, Fredriksson I, Hultin H, Mani M, Norlén O. Postoperative complications after breast cancer surgery and effect on recurrence and survival: population-based cohort study. *BJS Open*. 2024 Oct 29;8(6):zrae137. doi: 10.1093/bjsopen/zrae137. PMID: 39673757

Augustinsson A, Loman N, Ehrencrona H. Retrospective genetic testing (Traceback) in women with early-onset breast cancer after revised national guidelines: a clinical implementation study. *Breast Cancer Res Treat*. 2024 Jun;205(3):599-607. doi: 10.1007/s10549-024-07288-9. Epub 2024 Mar 16. PMID: 38491334

Boissin C, Wang Y, Sharma A, Weitz P, Karlsson E, Robertson S, Hartman J, Rantalainen M. Deep learning-based risk stratification of preoperative breast biopsies using digital whole slide images. *Breast Cancer Res*. 2024 Jun 3;26(1):90. doi: 10.1186/s13058-024-01840-7. PMID: 38831336

Boman C, Liu X, Eriksson Bergman L, Sun W, Tranchell C, Toli MA, Acs B, Bergh J, Foukakis T, Matikas A. A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression. *Br J Cancer*. 2024 Sep;131(4):718-728. doi: 10.1038/s41416-024-02777-6. Epub 2024 Jun 28. PMID: 38942987

Boraka Ö, Sartor H, Sturesdotter L, Hall P, Borgquist S, Zackrisson S, Rosendahl AH. WHO-recommended levels of physical activity in relation to mammographic breast density, mammographic tumor appearance, and mode of detection of breast cancer. *Breast Cancer Res*. 2024 Sep 20;26(1):136. doi: 10.1186/s13058-024-01889-4. PMID: 39304951

Conte B, Brasó-Maristany F, Hernández AR, Pascual T, Villacampa G, Schettini F, et al. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies. *EBioMedicine*. 2024 Apr;102:105043. doi:10.1016/j.ebiom.2024.105043. PMID: 38447275

Davidson AL, Michailidou K, Parsons MT, Fortuno C, Bolla MK, Wang Q, et al. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset. *Am J Hum Genet*. 2024 Sep 5;111(9):2059-2069. doi: 10.1016/j.ajhg.2024.07.004. PMID: 39096911

De Jong A, Von Wachenfeldt A, Nyström L, Andersson A. Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences. *Acta Oncol*. 2024 Nov 24;63:901-908. doi: 10.2340/1651-226X.2024.40575. PMID: 39582228

De Marchi T, Lai CF, Simmons GM, Goldsbrough I, Harrod A, Lam T, Buluwela L, Kjellström S, Brueffer C, Saal LH, Malmström J, Ali S, Niméus E. Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling. *Sci Rep*. 2024 Mar 22;14(1):6873. doi: 10.1038/s41598-024-56412-8. PMID: 38519482

Digkas E, Smith DR, Wennstig AK, Matikas A, Tegnélius E, Valachis A. Incidence and risk factors of hypothyroidism after treatment for early breast cancer: a population-based cohort study. *Breast Cancer Res Treat*. 2024 Feb;204(1):79-87. doi: 10.1007/s10549-023-07184-8. PMID: 38057688

Ekholm A, Wang Y, Vallon-Christersson J, Boissin C, Rantalainen M. Prediction of gene expression-based breast cancer proliferation scores from histopathology whole slide images using deep learning. *BMC Cancer*. 2024 Dec 11;24(1):1510. doi: 10.1186/s12885-024-13248-9. PMID: 39663527

Gabrielson M, Hammarström M, Bergqvist J, Lång K, Rosendahl AH, Borgquist S, Hellgren R, Czene K, Hall P. Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change. *Int J Cancer*. 2024 Jul 15;155(2):339-351. doi: 10.1002/ijc.34939. Epub 2024 Mar 30. PMID: 38554131

Gkekos L, Lundberg FE, Humphreys K, Fredriksson I, Johansson ALV. Worse prognosis in breast cancer diagnosed during second trimester pregnancy. *ESMO Open*. 2024 Apr;9(4):102972. doi: 10.1016/j.esmoop.2024.102972. PMID: 38520846

Gkekos L, Johansson ALV, Rodriguez-Wallberg KA, Fredriksson I, Lundberg FE. Obstetric and perinatal outcomes in women with previous breast cancer: a nationwide study of singleton births 1973-2017. *Hum Reprod Open*. 2024 May 4;2024(2):hoae027. doi: 10.1093/hropen/hoae027. eCollection 2024. PMID: 38784055

Godina C, Pollak MN, Jernström H. Targeting IGF-IR improves neoadjuvant chemotherapy efficacy in breast cancers with low IGFBP7 expression. *NPJ Precis Oncol*. 2024 Oct 3;8(1):212. doi: 10.1038/s41698-024-00712-9. PMID: 39362991

Godina C, Khazaei S, Belting M, Vallon-Christersson J, Nodin B, Jirström K, Isaksson K, Bosch A, Jernström H. High Caveolin-1 mRNA expression in triple-negative breast cancer is associated with an aggressive tumor microenvironment, chemoresistance, and poor clinical outcome. *PLoS One*. 2024 Jul 3;19(7):e0305222. doi: 10.1371/journal.pone.0305222. PMID: 38959243

Grassmann F, Mälarstig A, Dahl L, Bendes A, Dale M, Thomas CE, Gabrielsson M, Hedman ÅK, Eriksson M, Margolin S, Huang TH, Ulfstedt M, Forsberg S, Eriksson P, Johansson M, Hall P, Schwenk JM, Czene K. The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk. *Br J Cancer*. 2024 Mar;130(4):620-627. doi: 10.1038/s41416-023-02541-2. PMID: 38135714

Gümüşcü R, Unukovych D, Wärnberg F, de Boniface J, Sund M, Åhsberg K, Hansson E, Folkvaljon F, Mani M. National long-term patient-reported outcomes following mastectomy with or without breast reconstruction: The Swedish Breast Reconstruction Outcome Study Part 2 (SweBRO 2). *BJS Open*. 2024 Jan 3;8(1):zrae003. doi: 10.1093/bjsopen/zrae003. PMID: 38415759

Gümüşcü R, Wärnberg F, de Boniface J, Sund M, Åhsberg K, Hansson E, Folkvaljon F, Unukovych D, Mani M. Timing and type of breast reconstruction in SweBRO 3: long-term outcomes. *Br J Surg*. 2024 Aug 30;111(9):zxae240. doi: 10.1093/bjs/zxae240. PMID: 39316573

Göransson S, Hernández-Varas P, Hammarström M, Hellgren R, Bäcklund M, Lång K, Rosendahl AH, Eriksson M, Borgquist S, Strömblad S, Czene K, Hall P, Gabrielson M. Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial. *Breast Cancer Res*. 2024 Nov 26;26(1):163. doi: 10.1186/s13058-024-01919-1. PMID: 39593191

Haas CB, Chen H, Harrison T, Fan S, Gago-Dominguez M, Castelao JE, et al. Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization. *Breast Cancer Res Treat.* 2024 Jul;206(2):295-305. doi: 10.1007/s10549-024-07306-w. Epub 2024 Apr 24. PMID: 38653906

Hammarström M, Gabrielson M, Bergqvist J, Lundholm C, Crippa A, Bäcklund M, Wengström Y, Borgquist S, Eliasson E, Eriksson M, Tapia J, Czene K, Hall P. Influence of endoxifen on mammographic density-results from the KARISMA trial. *J Natl Cancer Inst.* 2024 Nov 8:djae280. doi: 10.1093/jnci/djae280. Online ahead of print. PMID: 39514025

Hosseini-Mellner S, Wickberg Å, Karakatsanis A, Valachis A. Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based study. *Breast.* 2024 Aug;76:103741. doi: 10.1016/j.breast.2024.103741. Epub 2024 May 9. PMID: 38759576

Jafer F, Malki S, Akram M, Gulwarisdotter T, Karakatsanis A, Valachis A. Postmastectomy radiation therapy in breast cancer patients with micrometastatic disease in sentinel node dissection: A cohort study and *meta*-analysis. *Clin Transl Radiat Oncol.* 2024 Mar 25;46:100770. doi: 10.1016/j.ctro.2024.100770. eCollection 2024 May. PMID: 38586080

Jonsson H, Andersson A, Mao Z, Nyström L. Age-specific differences in breast cancer treatment between screen-detected and non-screen-detected breast cancers in women aged 40-74 years at diagnosis in Sweden 2008-2017. *Acta Oncol.* 2024 Jul 5;63:552-556. doi: 10.2340/1651-226X.2024.40200. PMID: 38967249

Jonsson H, Andersson A, Mao Z, Nyström L. Age-specific differences in tumour characteristics between screen-detected and non-screen-detected breast cancers in women aged 40-74 at diagnosis in Sweden from 2008 to 2017. *J Med Screen.* 2024 Mar 7:9691413241237616. doi: 10.1177/09691413241237616. PMID: 38454634

Kim K, Sweeting M, Wilking N, Jönsson L. General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in Sweden. *Med Decis Making.* 2024 Oct;44(7):843-853. doi: 10.1177/0272989X241275969. PMID: 39263806

Liu Y, Johansson ALV, Oikonomou I, Frisell A, Adam HC, Ansarei D, Halle M, Sackey H, de Boniface J. Surgical complications after immediate implant-based breast reconstruction for breast cancer in women over 65 years. *BJS Open.* 2024 Sep 3;8(5):zrae095. doi: 10.1093/bjsopen/zrae095. PMID: 39382121

Lundberg FE, Stensheim H, Ullenhag GJ, Sahlgren HM, Lindemann K, Fredriksson I, Johansson ALV. Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden - a population-based study. *Acta Obstet Gynecol Scand.* 2024 Apr;103(4):669-683. doi: 10.1111/aogs.14677. PMID: 37694965

Mao X, He W, Humphreys K, Eriksson M, Holowko N, Yang H, Tapia J, Hall P, Czene K. Breast Cancer Incidence After a False-Positive Mammography Result. *JAMA Oncol.* 2024 Jan 1;10(1):63-70. doi: 10.1001/jamaoncol.2023.4519. PMID: 37917078

Meng P, Dalal H, Chen Y, Brueffer C, Gladchuk S, Alcaide M, Ehinger A, Saal LH. Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab. *NPJ Breast Cancer*. 2024 Feb 19;10(1):14. doi: 10.1038/s41523-024-00621-x. PMID: 38374091

Mulder CV, Yang X, Jee YH, Scott CG, Gao C, Cao Y, Hurson AN, Eriksson M, Vachon CM, Hall P, Antoniou AC, Kraft P, Gierach GL, Garcia-Closas M, Choudhury PP. Investigating the added value of incorporating mammographic density to an integrated breast cancer risk model with questionnaire-based risk factors and polygenic risk score. *Res Sq*. 2024 Dec 19;rs.3.rs-5445786. doi: 10.21203/rs.3.rs-5445786/v1. PMID: 39764121

Orsini L, Czene K, Humphreys K. Random effects models of tumour growth for investigating interval breast cancer. *Stat Med*. 2024 Jul 10;43(15):2957-2971. doi: 10.1002/sim.10105. PMID: 38747450

Palmér S, Blomqvist C, Holmqvist M, Lindman H, Lambe M, Ahlgren J. Validation of primary and outcome data **quality** in a Swedish population-based **breast cancer quality** registry. *BMC Cancer*. 2024 Mar 11;24(1):329. doi: 10.1186/s12885-024-12073-4. PMID: 38468209

Rask G, Wadsten C, Acs B, Hartman J, Fredriksson I, Garmo H, Wärnberg F, Sund M. Immune cell infiltrate in ductal carcinoma in situ and the risk of dying of breast cancer: case-control study. *Br J Surg*. 2024 Jan 31;111(2):znae037. doi: 10.1093/bjs/znae037. PMID: 38395442

Rodriguez J, Grassmann F, Xiao Q, Eriksson M, Mao X, Bajalica-Lagercrantz S, Hall P, Czene K. Investigation of Genetic Alterations Associated With Interval Breast Cancer. *JAMA Oncol*. 2024 Jan 25:e236287. doi: 10.1001/jamaoncol.2023.6287. PMID: 38270937

Roostee S, Ehinger D, Jönsson M, Phung B, Jönsson G, Sjö Dahl G, Staaf J, Aine M. Tumour immune characterisation of primary triple-negative breast cancer using automated image quantification of immunohistochemistry-stained immune cells. *Sci Rep*. 2024 Sep 13;14(1):21417. doi: 10.1038/s41598-024-72306-1. PMID: 39271910

Sasiain I, Nacer DF, Aine M, Veerla S, Staaf J. Tumor purity estimated from bulk DNA methylation can be used for adjusting beta values of individual samples to better reflect tumor biology. *NAR Genom Bioinform*. 2024 Nov 4;6(4):lqae146. doi: 10.1093/nargab/lqae146. PMID: 39498434

Schiza A, Fredriksson I, Sund M, Valchis A. Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study. *Breast Cancer Res Treat*. 2024 Jan;203(2):235-243. doi: 10.1007/s10549-023-07129-1. doi: 10.1007/s10549-023-07129-1. PMID: 37812362

Sharma A, Lövgren SK, Eriksson KL, Wang Y, Robertson S, Hartman J, Rantalainen M. Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images. *Breast Cancer Res*. 2024 Aug 14;26(1):123. doi: 10.1186/s13058-024-01879-6. PMID: 39143539

Sharma A, Weitz P, Wang Y, Liu B, Vallon-Christersson J, Hartman J, Rantalainen M. Development and prognostic validation of a three-level NHG-like deep learning-based model for histological grading of breast cancer. *Breast Cancer Res*. 2024 Jan 29;26(1):17. doi: 10.1186/s13058-024-01770-4. PMID: 38287342

Sigurjonsdottir G, De Marchi T, Ehinger A, Hartman J, Ullén S, Leandersson K, Bosch A, Staaf J, Killander F, Niméus E. Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort. *Breast Cancer Res Treat.* 2024 Dec 10. doi: 10.1007/s10549-024-07561-x. PMID: 39656429

Skarping I, Ellbrant J, Dihge L, Ohlsson M, Huss L, Bendahl PO, Rydén L. Retrospective validation study of an artificial neural network-based preoperative decision-support tool for noninvasive lymph node staging (NILS) in women with primary breast cancer (ISRCTN14341750). *BMC Cancer.* 2024 Jan 16;24(1):86. doi: 10.1186/s12885-024-11854-1. PMID: 38229058

Solorzano L, Robertson S, Acs B, Hartman J, Rantalainen M. Ensemble-based deep learning improves detection of invasive breast cancer in routine histopathology images. *Heliyon.* 2024 Jun 14;10(12):e32892. doi: 10.1016/j.heliyon.2024.e32892. PMID: 39022088

Strell C, Smith D R, Valachis A, Woldeyesus H, Wadsten C, Fredriksson I, Micke P, Schiza A. Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study. *Breast Cancer Res Treat.* 2024 Sep;207(2):293-299. doi: 10.1007/s10549-024-07358-y. PMID: 38763971

Svensson M, Bendahl PO, Alkner S, Hansson E, Rydén L, Dihge L. Development and Validation of Prediction Models for Sentinel Lymph Node Status Indicating Postmastectomy Radiotherapy in Breast Cancer: a Population-Based Study of 18 185 Women. *Res Square* 2024 DOI: 10.1101/2024.02.21.24303165

Söderberg E, Wärnberg F, Wennstig AK, Nilsson G, Garmo H, Holmberg L, Blomqvist C, Sund M, Wadsten C. Association of clinicopathologic variables and patient preference with the choice of surgical treatment for early-stage breast cancer: A registry-based study. *Breast.* 2024 Feb;73:103614. doi: 10.1016/j.breast.2023.103614. PMID: 38056168

Veerla S, Staaf J. Kataegis in clinical and molecular subgroups of primary breast cancer. *NPJ Breast Cancer.* 2024 Apr 24;10(1):32. doi: 10.1038/s41523-024-00640-8. PMID: 38658600

Vermani L, Barnekow E, Liu W, Wendt C, Hall P, Margolin S, Lindblom A. Swedish Genome-Wide Haplotype Association Analysis Suggests Breast Cancer Loci with Varying Risk-Modifying Effects. *Genes (Basel).* 2024 Dec 17;15(12):1616. doi: 10.3390/genes15121616. PMID: 39766883

Vidal JM, Tsiknakis N, Staaf J, Bosch A, Ehinger A, Nimeus E, Salgado R, Bai Y, Rimm DL, Hartman J, Acs B. The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably? *EClinicalMedicine.* 2024 Nov 15;78:102928. doi: 10.1016/j.eclinm.2024.102928. PMID: 39634035

Weitz P, Valkonen M, Solorzano L, Carr C, Kartasalo K, Boissin C, et al. The ACROBAT 2022 challenge: Automatic registration of breast cancer tissue. *Med Image Anal.* 2024 Oct;97:103257. doi: 10.1016/j.media.2024.103257. PMID: 38981282

Wide A, Ahlgren J, Smedby KE, Hellman K, Henriksson R, Ståhl O, Lampic C, Wettergren L. Health-related quality of life and supportive care needs in young adult cancer survivors-a

longitudinal population-based study. *Support Care Cancer*. 2024 Oct 22;32(11):742. doi: 10.1007/s00520-024-08896-3.PMID: 39436421

Xiao Q, Mao X, Ploner A, Grassmann F, Rodriguez J, Eriksson M, Hall P, Czene K. Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer. *J Natl Cancer Inst*. 2024 Feb 14:djae030. doi: 10.1093/jnci/djae030. PMID: 38366028

Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla MK, et al. Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction. *Breast Cancer Res*. 2024 Dec 29;26(1):189. doi: 10.1186/s13058-024-01947-x.PMID: 38410445

Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla MK, et al. Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction. *Breast Cancer Res*. 2024 Dec 29;26(1):189. doi: 10.1186/s13058-024-01947-x.PMID: 39734228

Zanti M, O'Mahony DG, Parsons MT, Dorling L, Dennis J, Boddicker NJ, et al. Analysis of more than 400,000 women provides case-control evidence for *BRCA1* and *BRCA2* variant classification. *medRxiv*. 2024 Sep 4:2024.09.04.24313051. doi: 10.1101/2024.09.04.24313051.PMID: 39281752

Zeng E, He W, Sjölander A, Bergqvist J, Fang F, Czene K. Familial adversity: association with discontinuation of adjuvant hormone therapy and breast cancer prognosis. *J Natl Cancer Inst*. 2024 Jun 7;116(6):920-928. doi: 10.1093/jnci/djae061. PMID: 38471102

2023

Becherer BE, Hopper I, Cooter RD, Couturaud B, von Fritschen U, Mullen E, Perks AGB, Pusic AL, Stark B, Mureau MAM, Rakhorst HA. Comparing 200,000 Breast Implants and 85,000 Patients over Four National Breast Implant Registries. *Plast Reconstr Surg*. 2023 Aug 1;152(2):307-318. doi: 10.1097/PRS.00000000000010208. Epub 2023 Jul 27.PMID: 36728275

Bengtsson Y, Demircan K, Vallon-Christersson J, Malmberg M, Saal LH, Rydén L, Borg Å, Schomburg L, Sandsveden M, Manjer J. Serum copper, zinc and copper/zinc ratio in relation to survival after breast cancer diagnosis: A prospective multicenter cohort study. *Redox Biol*. 2023 Jul;63:102728. Epub 2023 May 16.

Boraka Ö, Klintman M, Vallon-Christersson J, Zackrisson S, Hall P, Borgquist S, Rosendahl AH. FGF/FGFR1 system in paired breast tumor-adjacent and tumor tissues, associations with mammographic breast density and tumor characteristics. *Frontiers in Oncology*. 2023 Jul 20;13:1230821. doi: 10.3389/fonc.2023.1230821.

Cossío F, Schurz H, Engström M, Barck-Holst C, Tsirikoglou A, Lundström C, Gustafsson H, Smith K, Zackrisson S, Strand F. VAI-B: a multicenter platform for the external validation of artificial intelligence algorithms in breast imaging. *J Med Imaging (Bellingham)*. 2023 Nov;10(6):061404. doi: 10.1117/1.JMI.10.6.061404. Epub 2023 Mar 20.PMID: 36949901

Dahlblom V, Dustler M, Bolejko A, Bakic PR, Granberg H, Johnson K, Förnvik D, Lång K, Tingberg A, Zackrisson S. Malmö Breast ImaginG database: objectives and development. *J Med Imaging (Bellingham)*. 2023 Nov;10(6):061402. doi: 10.1117/1.JMI.10.6.061402. PMID: 36779038

de Boniface J, Szulkin R, Johansson ALV. Medical and surgical postoperative complications after breast conservation versus mastectomy in older women with breast cancer: Swedish population-based register study of 34 139 women. *Br J Surg* 2023 Feb 15;110(3):344-352. doi: 10.1093/bjs/znac411. PMID: 36511352

De Marchi T, Pyl PT, Sjöström M, Reinsbach SE, DiLorenzo S, Nystedt B, Tran L, Pekar G, Wärnberg F, Fredriksson I, Malmström P, Fernö M, Malmström L, Malmstöm J, Niméus E. Proteogenomics decodes the evolution of human ipsilateral breast cancer. *Commun Biol*. 2023 Feb 2;6(1):139. doi: 10.1038/s42003-023-04526-6. PMID: 36732562

Dembrower K, Salim M, Eklund M, Lindholm P, Strand F. Implications for downstream workload based on calibrating an artificial intelligence detection algorithm by standalone-reader or combined-reader sensitivity matching. *J Med Imaging (Bellingham)*. 2023 Feb;10(Suppl 2):S22405. doi: 10.1117/1.JMI.10.S2.S22405. Epub 2023 Apr 5. PMID: 37035276

Dembrower K, Crippa A, Colón E, Eklund M, Strand F; ScreenTrustCAD Trial Consortium. Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study. *Lancet Digit Health*. 2023 Oct;5(10):e703-e711. doi: 10.1016/S2589-7500(23)00153-X. Epub 2023 Sep 8. PMID: 37690911

Demircan K, Bengtsson Y, Chillon TS, Vallon-Christersson J, Sun Q, Larsson C, Malmberg M, Saal LH, Rydén L, Borg Å, Manjer J, Schomburg L. Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study. *J Transl Med*. 2023 Sep 23;21(1):658. doi: 10.1186/s12967-023-04502-y. PMID: 37741974

Enlund M, Berglund A, Enlund A, Lundberg J, Wärnberg F, Wang D-X, Ekman A, Ahlstrand R, Flisberg P, Hedlund L, Östlund I, Bergkvist L. Impact of general anaesthesia on breast cancer survival: a 5-year follow up of a pragmatic, randomised, controlled trial, the CAN-study, comparing propofol and sevoflurane. *eClinicalMedicine* 2023;60: 102037

Eriksson M, Czene K, Vachon C, Conant EF, Hall P. Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer. *J Clin Oncol*. 2023 May 10; 41(14): 2536–2545. doi: 10.1200/JCO.22.01564. PMID: 36930854

Figlioli G, Billaud A, Ahearn TU, Antonenkova NN, Becher H, Beckmann MW, Behrens S, et al. FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women. *Eur J Hum Genet*. 2023 Jan 27. doi: 10.1038/s41431-022-01257-w.

Grassmann F, Mälärstig A, Dahl L, Bendes A, Dale M, Thomas CE, Gabrielsson M, Hedman ÅK, Eriksson M, Margolin S, Huang TH, Ulfstedt M, Forsberg S, Eriksson P, Johansson M, Hall P, Schwenk JM, Czene K. The impact of circulating protein levels identified by affinity proteomics on short-term, overall breast cancer risk. *Br J Cancer*. 2023 Dec 22. doi: 10.1038/s41416-023-02541-2. Online ahead of print. PMID: 38135714

Gulis K, Ellbrant J, Svensjö T, Skarping I, Vallon-Christersson J, Loman N, Bendahl PO, Rydén L. A prospective cohort study identifying radiologic and tumor related factors of importance for breast conserving surgery after neoadjuvant chemotherapy. *Eur J Surg Oncol*. 2023 Jul;49(7):1189-1195. Epub 2023 Mar 28.

Hammarström M, Gabrielson M, Crippa A, Discacciati A, Eklund M, Lundholm C, Bäcklund M, Wengström Y, Borgquist S, Bergqvist J, Eriksson M, Tapia J, Czene K, Hall P. Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women. *British Journal of Cancer*. 2023 May 6. doi: 10.1038/s41416-023-02293-z.

He W, Zeng E, Sjölander A, Hübbert L, Hedayati E, Czene K. Concomitant Discontinuation of Cardiovascular Therapy and Adjuvant Hormone Therapy Among Patients With Breast Cancer. *JAMA Netw Open*. 2023 Jul 3;6(7):e2323752. doi: 10.1001/jamanetworkopen.2023.23752.PMID: 37459096

Hjærtström M, Dihge L, Bendahl PO, Skarping I, Ellbrant J, Ohlsson M, Rydén L. Noninvasive Staging of Lymph Node Status in Breast Cancer Using Machine Learning: External Validation and Further Model Development. *JMIR Cancer*. 2023 Nov 20;9:e46474. doi: 10.2196/46474.PMID: 37983068

Hovén E, Flynn KE, Weinfurt KP, Eriksson LE, Wttergren L. Psychometric evaluation of the Swedish version of the PROMIS Sexual Function and Satisfaction Measures in clinical and nonclinical young adult populations. *Sex Med* 2023 Jan 12;11(1):qfac006. doi: 10.1093/sexmed/qfac006. PMID: 37007849

Hu K, Feychting M, Lu D, Sjolander A, Czene K, Hall P, Fang F. Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Breast Cancer: Evidence from a General Female Population and a Mammographic Screening Cohort in Sweden. *Cancers (Basel)*. 2023;15(3). PMC9913077.

Hubbert L, Mallios P, Karlström P, Papakonstantinou A, Bergh J, Hedayati E. Long-term and real-life incidence of cancer therapy-related cardiovascular toxicity in patients with breast cancer: a Swedish cohort study. *Front Oncol* 2023 Apr 19;13:1095251. doi: 10.3389/fonc.2023.1095251. PMID: 37152049

Illipse M, Czene K, Hall P, Humphreys K. Studying the association between longitudinal mammographic density measurements and breast cancer risk: a joint modelling approach. *Breast Cancer Research*. 2023 Jun 9;25(1):64. doi: 10.1186/s13058-023-01667-8.

Janeva S, Parris TZ, Krabbe E, Sundquist M, Karlsson P, Audisio RA, Olofsson Bagge R, Kovács A. Clinical relevance of biomarker discordance between primary breast cancers and synchronous axillary lymph node metastases. *Clin Exp Metastasis*. 2023 Aug;40(4):299-308. doi: 10.1007/s10585-023-10214-w. Epub 2023 Jul 1.PMID: 37392277

Johnsson A, Kiani NA, Gernaat SAM, Wilking U, Shabo I, Hedayati E. Planning for return to work during the first year after breast cancer metastasis: A Swedish cohort study. *Cancer Med* 2023 May;12(9):10840-10850. PMID: 36880198. doi: 10.1002/cam4.5752.

Justo N, Wilking N, Jönsson L. Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden. *Clinical Drug Investigation* doi:10.1007/s40261-023-01279-2

Lopes Cardozo JMN, Andrulis IL, Bojesen SE, Dörk T, Eccles DM, Fasching PA, Hoening MJ, Keeman R, Nevanlinna H, Rutgers EJT, Easton DF, Hall P, Pharoah PDP, van 't Veer LJ, Schmidt MK; Breast Cancer Association Consortium and MINDACT Collaborators. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. *J Clin Oncol*. 2023 Jan 23;JCO2201978. doi: 10.1200/JCO.22.01978.

Lundberg FE, Ghekos L, Rodriguez-Wallberg KA, Fredriksson I, Johansson ALV. Risk of obstetric and perinatal complications in women presenting with breast cancer during pregnancy and the first year postpartum in Sweden 1973-2017: A population-based matched study. *Acta Obstet Gynecol Scand*. 2023 Mar 23. doi: 10.1111/aogs.14555. PMID: 36959086

Lång K, Josefsson V, Larsson AM, Larsson S, Högberg C, Sartor H, Hofvind S, Andersson I, Rosso A. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. *Lancet Oncol*. 2023 Aug;24(8):936-944. doi: 10.1016/S1470-2045(23)00298-X. PMID: 37541274

Mao X, He W, Humphreys K, Eriksson M, Holowko N, Strand F, Hall P, Czene K. Factors Associated With False-Positive Recalls in Mammography Screening. *Journal of the National Comprehensive Cancer Network*. 2023;21(2):143-52 e4.

Mao X, He W, Eriksson M, Lindström LS, Bajalica-Lagercrantz S, Hammarström M, Grassmann F, Humphreys K, Easton D, Hall P, Czene K. Prediction of breast cancer risk for sisters of women attending screening. *J Natl Cancer Inst* 2023 May 27;djad101. doi: 10.1093/jnci/djad101. PMID: 37243694

Mariapun S, Ho WK, Eriksson M, Tai MC, Mohd Taib NA, Yip CH, Rahmat K, Li J, Hartman M, Hall P, Easton DF, Lindstrom S, Teo SH. Evaluation of SNPs associated with mammographic density in European women with mammographic density in Asian women from South-East Asia. *Breast Cancer Research and Treatment*. 2023 Sep;201(2):237-245. doi: 10.1007/s10549-023-06984-2.

Morra A, Schreurs MAC, Andrulis IL, Anton-Culver H, Augustinsson A, Beckmann MW et al. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. *Cancer Med*. 2023 Aug;12(15):16142-16162. doi: 10.1002/cam4.6272. Epub 2023 Jul 3. PMID: 37401034

Mälärstig A, Grassmann F, Dahl L, Dimitriou M, McLeod D, Gabrielson M, Smith-Byrne K, Thomas CE, Huang TH, Forsberg SKG, Eriksson P, Ulfstedt M, Johansson M, Sokolov AV, Schiöth HB, Hall P, Schwenk JM, Czene K, Hedman ÅK. Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation. *Nature Communications*. 2023 Nov 24;14(1):7680. doi: 10.1038/s41467-023-43485-8.

Nacer DF, Vallon-Christersson J, Nordborg N, Ehrencrona H, Kvist A, Borg Å, Staaf J. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study. *Genome Med*. 2023 Apr 14;15(1):25.

Salim M, Dembrower K, Eklund M, Smith K, Strand F. Differences and similarities in false interpretations by AI CAD and radiologists in screening mammography. *Br J Radiol*. 2023 Nov;96(1151):20230210. doi: 10.1259/bjr.20230210. Epub 2023 Sep 3. PMID: 37660400

Schiza A, Fredriksson I, Sund M, Valachis A. De novo metastatic breast cancer in men vs women: a Swedish population-based cohort study. *JNCI Cancer Spectr* 2023 Jul 3;7(4):pkad050. doi: 10.1093/jncics/pkad050. PMID: 37490458

Sigurjonsdottir G, De Marchi T, Ehinger A, Hartman J, Bosch A, Staaf J, Killander F, Niméus E. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms. *Breast Cancer Res.* 2023 Oct 10;25(1):123.

Skourlis N, Crowther MJ, Andersson TML, Lu D, Lambe M, Lambert PC. Exploring different research questions via complex multi-state models when using registry-based repeated prescriptions of antidepressants in women with breast cancer and a matched population comparison group. *BMC Med Res Methodol* 2023 Apr 10;23(1):87. doi: 10.1186/s12874-023-01905-9. PMID: 37038100

Strandberg R, Czene K, Hall P, Humphreys K. Novel predictions of invasive breast cancer risk in mammography screening cohorts. *Statistics in Medicine.* 2023 Sep 20;42(21):3816-3837. doi: 10.1002/sim.9834.

Strandberg R, Illipse M, Czene K, Hall P, Humphreys K. Influence of mammographic density and compressed breast thickness on true mammographic sensitivity: a cohort study. *Scientific Reports.* 2023 Aug 30;13(1):14194. doi: 10.1038/s41598-023-41356-2.

Sund M, Garmo, H, Andersson A, Margolin S, Ahlgren J, Valachis A. Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk. *Breast Cancer Res Treat* 2023 Feb 11. doi: 10.1007/s10549-023-06871-w. PMID: 36773184

Sundén M, Norgren S, Lundqvist R, Andersson A, Sund M, Hemmingsson O. Receptor conversion and survival in breast cancer liver metastases. *Breast Cancer Res.* 2023 Sep 13;25(1):105. doi: 10.1186/s13058-023-01706-4. PMID: 37705026

Söderberg E, Wärnberg F, Wennstig AK, Nilsson G, Garmo H, Holmberg L, Blomqvist C, Sund M, Wadsten C. Association of clinicopathologic variables and patient preference with the choice of surgical treatment for early-stage breast cancer: A registry-based study. *Breast.* 2023 Nov 30;73:103614. doi: 10.1016/j.breast.2023.103614. PMID: 38056168

Tabar L, Dean PB, Tucker FL, Puchkova O, Bozo R, Yen AMF, Chen SLS, Smith RA, Duffy SW, Chen THH. The challenging imaging and histopathologic features of diffusely infiltrating breast cancer. *Eur J Radiol* 2023 Apr;161:110754. doi: 10.1016/j.ejrad.2023.110754. PMID: 36868061

Thorén L, Margolin S, Eliasson, Bergh J, Lindh. Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records. *Breast Cancer Res Treat* 2023 Apr;198(3):499-508. doi: 10.1007/s10549-023-06887-2. Epub 2023 Mar 1.

Thurell J, Manouchehr N, Fredriksson I, Wilking U, Bergh J, Ryden L, Koppert LB, Karsten MM, Kiani NA, Hedayati E. Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage breast cancer: a Swedish retrospective cohort study. *Breast* 2023 Aug;70:18-24. doi: 10.1016/j.breast.2023.05.008. Epub 2023 Jun 1. PMID: 37295176

Wang QL, Zhang Y, Zeng E, Grassmann F, He W, Czene K. Risk of estrogen receptor-specific breast cancer by family history of estrogen receptor subtypes and other cancers. *J Natl Cancer Inst.* 2023 Sep 7;115(9):1020-1028. doi: 10.1093/jnci/djad104.PMID: 37243749

Wang Y, Ali MA, Vallon-Christersson J, Humphreys K, Hartman J, Rantalainen M. Transcriptional intra-tumour heterogeneity predicted by deep learning in routine breast histopathology slides provides independent prognostic information. *Eur J Cancer.* 2023 Sep;191:112953

Zhang Y, Wang QL, Zeng E, He W, Czene K. Analysis of Breast Cancer Family History, Estrogen Receptor Status, and Breast Cancer Outcomes in Sweden. *JAMA Netw Open.* 2023 Jun 1;6(6):e2318053. doi:10.1001/jamanetworkopen.2023.18053. PMID: 37310740

Öfverholm A, Törngren T, Rosén A, Arver B, Einbeigi Z, Haraldsson K, Ståhlbom AK, Kuchinskaya E, Lindblom A, Melin B, Paulsson-Karlsson Y, Stenmark-Askmalin M, Tham E, von Wachenfeldt A, Kvist A, Borg Å, Ehrencrona H. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. *BMC Cancer.* 2023 Aug 10;23(1):738. doi: 10.1186/s12885-023-11229-y.PMID: 37563628

2022

Ahearn TU, Zhang H, Michailidou K, Milne R et al. Common variants in breast cancer risk loci predispose to distinct tumor subtypes. *Breast Cancer Res* 2022 Jan 4;24(1):2. doi: 10.1186/s13058-021-01484-x. PMID: 34983606

Altena R, Gernaat SAM, Wilking U, Kiani NA, Johnsson A, Hedayati E. Use of sickness benefits by patients with metastatic breast cancer-A Swedish cohort study. *Eur J Cancer Care (Engl).* 2022 Sep;31(5):e13626. doi: 10.1111/ecc.13626. PMID: 35621269

Bai Y, Cole K, Martinez-Morilla S, Ahmed FS, Zugazagoitia J, Staaf J, Bosch A, Ehinger A, Nimeus E, Hartman J, Acs B, Rimm DL. An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer. *Clin Cancer Res.* 2021 Oct 15; 27(20): 5557–5565. doi: 10.1158/1078-0432.CCR-21-0325.

Barnekow E, Liu W, Helgadóttir HT, Michailidou K, Dennis J, Bryant P, Thutkawkorapin J, Wendt C, Czene K, Hall P, Margolin S and Lindblom A. A Swedish Genome-Wide Haplotype Association Analysis Identifies a Novel Breast Cancer Susceptibility Locus in 8p21.2 and Characterizes Three Loci on Chromosomes 10, 11 and 16. *Cancers (Basel).* 2022;14(5). PMC8909613

Bengtsson Y, Demircan K, Rosendahl AH, Borgquist S, Sandsveden M, Manjer J. Zinc and Breast Cancer Survival: A Prospective Cohort Study of Dietary Intake and Serum Levels. *Nutrients.* 2022 Jun 22;14(13):2575. doi: 10.3390/nu14132575. PMID: 35807763; PMCID: PMC9268140.

Boman C, Edman Kessler L, Bergh J, Matikas A, Foukakis T. Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study. *Breast Cancer Res Treat*. 2022 Jul;194(1):49-56. doi: 10.1007/s10549-022-06591-7. PMID: 35461374

Bäcklund M, Eriksson M, Hammarström M, Thoren L, Bergqvist J, Margolin S, Hellgren R, Wengström Y, Gabrielson M, Czene K, Hall P. Time to Mammographic Density Decrease After Exposure to Tamoxifen. *Oncologist*. 2022 Jul 5;27(7):e601-e603. doi: 10.1093/oncolo/oyac104.PMID: 35605013

Chen H, Fan S, Stone J, Thompson DJ, Douglas J, Li S, Scott C, Bolla MK, Wang Q, Dennis J, et al. Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. *Breast Cancer Res*. 2022 Apr 12;24(1):27. doi: 10.1186/s13058-022-01524-0.

de Boniface J, Szulkin R, Johansson ALV. Major surgical postoperative complications and survival in breast cancer: Swedish population-based register study in 57 152 women. *Br J Surg*. 2022 Sep 9;109(10):977-983. doi:10.1093/bjs/znac275. PMID: 35929050

de Boniface J, Coudé Adam H, Frisell A, Oikonomou I, Ansarei D, Ljung Konstantinidou A, Liu Y, Abo Alniaj B, Wallmon P, Halle M, Johansson ALV, Sackey H. Long-term outcomes of implant-based immediate breast reconstruction with and without radiotherapy: a population-based study. *Br J Surg*. 2022 Oct 14;109(11):1107-1115. doi:10.1093/bjs/znac283. PMID: 35949111

de Boniface J, Szulkin R, Johansson ALV. Major surgical postoperative complications and survival in breast cancer: Swedish population-based register study in 57 152 women. *Br J Surg*. 2022 Sep 9;109(10):977-983. doi: 10.1093/bjs/znac275.PMID: 35929050

Demircan K, Sun Q, Bengtsson Y, Seemann P, Vallon-Christersson J, Malmberg M, Saal LH, Rydén L, Borg Å, Minich WB, Manjer J, Schomburg L. Autoimmunity to selenoprotein P is a novel independent predictor of breast cancer recurrence. *Redox Biol*. 2022 Jul;53:102346. doi: 10.1016/j.redox.2022.102346. PMID: 35636018

Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L, Bolla MK, Wang Q, Ahearn TU, et al. Rare germline copy number variants (CNVs) and breast cancer risk. *Commun Biol*. 2022 Jan 18;5(1):65. doi: 10.1038/s42003-021-02990-6.

Dixon-Suen SC, Lewis SJ, Martin RM, English DR, Boyle T, Giles GG, Michailidou K, Bolla MK, et al; Breast Cancer Association Consortium. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. *Br J Sports Med*. 2022 Oct;56(20):1157-1170. doi: 10.1136/bjsports-2021-105132.

Dorling L, Carvalho S, Allen J, Parsons MT, Fortuno C, González-Neira A, Heijl SM, Adank MA, et al. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. *Genome Med*. 2022 May 18;14(1):51. doi: 10.1186/s13073-022-01052-8.

Enlund M, Berglund A, Enlund A, Bergkvist L. Volatile versus Propofol General Anesthesia and Long-term Survival after Breast Cancer Surgery: A National Registry Retrospective Cohort Study. *Anesthesiology*. 2022 Sep 1;137(3):315-326. doi: 10.1097/ALN.0000000000004309. PMID: 35759394

Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BAM, Becher H, Blomqvist C, et al. PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients. *Breast Cancer Res.* 2022 Oct 21;24(1):69. doi: 10.1186/s13058-022-01567-3.

Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, et al. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. *Eur J Cancer.* 2022 Aug 4;173:178-193. doi: 10.1016/j.ejca.2022.06.011.

Harborg S, Ahern TP, Feldt M, Rosendahl AH, Cronin-Fenton D, Melander O, Borgquist S. Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study. *Breast Cancer Res Treat.* 2022 Feb;191(3):611-621. doi: 10.1007/s10549-021-06462-7. PMID: 34825306

Inasu M, Feldt M, Jernström H, Borgquist S, Harborg S. Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study. *Breast* 2022 Feb;61:123-128. doi: 10.1016/j.breast.2022.01.003. PMID: 34995921

Isheden G, Czene K, Humphreys K. Random effects models of lymph node metastases in breast cancer: quantifying the roles of covariates and screening using a continuous growth model. *Biometrics* 2022 Mar;78(1):376-387. doi: 10.1111/biom.13430. Epub 2021 Feb 7

Johansson A, Dar H, van 't Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, Benz CC, Esserman LJ, Stål O, Nordenskjöld B, Fornander T, Lindström LS. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial. *J Clin Oncol.* 2022 Dec 10;40(35):4071-4082. doi: 10.1200/JCO.21.02844. Epub 2022 Jul 21. PMID: 35862873

Jung AY, Ahearn TU, Behrens S, Middha P, Bolla MK, Wang Q, Arndt V, Aronson KJ, et al. Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies. *J Natl Cancer Inst.* 2022 Jun 20:djac117. doi: 10.1093/jnci/djac117

Klintman M, Rosendahl AH, Randeris B, Eriksson M, Czene K, Hall P, Borgquist S. Postmenopausal overweight and breast cancer risk; results from the KARMA cohort. *Breast Cancer Res Treat.* 2022 Nov;196(1):185-196. doi: 10.1007/s10549-022-06664-7

Marklund A, Lekberg T, Hedayati E, Liljegren A, Bergh J, Lundberg FE, Rodriguez-Wallberg KA. Relapse Rates and Disease-Specific Mortality Following Procedures for Fertility Preservation at Time of Breast Cancer Diagnosis. *JAMA Oncol.* 2022 Oct 1;8(10):1438-1446. doi: 10.1001/jamaoncol.2022.3677. PMID: 36006625

Mavaddat N, Dorling L, Carvalho S, Allen J, González-Neira A, Keeman R, et al. Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. *JAMA Oncol.* 2022 Jan 27:e216744. doi: 10.1001/jamaoncol.2021.6744. PMID: 35084436

Pistiolis L, Khaki D, Kovács A, Olofsson Bagge R. The Effect of Melatonin Intake on Survival of Patients with Breast Cancer-A Population-Based Registry Study. *Cancers (Basel).* 2022 Nov 29;14(23):5884. doi: 10.3390/cancers14235884. PMID: 36497366

Pousette J, Johansson A, Jönsson C, Fornander T, Lindström LS, Olsson H, Perez-Tenorio G. Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in

ER-Positive/HER2-Negative Postmenopausal Breast Cancer Patients. *Cancers (Basel)*. 2022 Oct 4;14(19):4844. doi: 10.3390/cancers14194844.PMID: 36230767

Skarping I, Nilsson K, Dihge L, Fridhammar A, Ohlsson M, Huss L, Bendahl PO, Steen Carlsson, K, Rydén L. The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer. *Breast Cancer Res Treat* 2022; 194: 577–586. doi: 10.1007/s10549-022-06636-x. PMID: 35790694

Staaf J, Häkkinen J, Hegardt C, Saal L, Kimbung S, Hedenfalk I, Lien T, Sørli T, Naume B, Russnes H, Marcone Jeitziner R, Ayyanan A, Brisken C, Malterling R, Asking B, Olofsson H, Lindman H, Bendahl PO, Ehinger A, Larsson C, Loman N, Ryden L, Malmberg M, Borg Å, Vallon-Christersson J. RNA Sequencing-Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early-Stage Breast Cancer. *NPJ Breast Cancer* 2022; Aug 16;8(1):94. doi: 10.1038/s41523-022-00465-3. PMID: 35974007

Strandberg R, Czene K, Eriksson M, Hall P and Humphreys K. Estimating Distributions of Breast Cancer Onset and Growth in a Swedish Mammography Screening Cohort. *Cancer Epidemiol Biomarkers Prev* 2022 Jan 13;cebp.1011.2021. doi: 10.1158/1055-9965.EPI-21-1011. PMID: 35027432

Tabár L, Dean PB, Lee Tucker F, Yen AM, Chen SL, Jen GHH, Wang JW, Smith RA, Duffy SW, Chen TH. A new approach to breast cancer terminology based on the anatomic site of tumour origin: The importance of radiologic imaging biomarkers. *Eur J Radiol*. 2022 Apr;149:110189. doi: 10.1016/j.ejrad.2022.110189. PMID: 35151954

Tabár L, Dean PB, Tucker FL, Yen AM, Fann JC, Lin AT, Smith RA, Duffy SW, Chen TH. Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB. *Eur J Radiol*. 2022 Jul;152:110323. doi: 10.1016/j.ejrad.2022.110323. PMID: 35576721

Tabár L, Dean PB, Lee Tucker F, Yen AM, Chang RW, Hsu CY, Smith RA, Duffy SW, Chen TH. Breast cancers originating from the major lactiferous ducts and the process of neoductogenesis: Ductal Adenocarcinoma of the Breast, DAB. *Eur J Radiol*. 2022 Aug;153:110363. doi: 10.1016/j.ejrad.2022.110363. Epub 2022 May 18. PMID: 35605334

Tabár L, Dean PB, Lee Tucker F, Chen TH, Smith RA, Duffy SW, Chiu SY, Ku MM, Fan CY, Yen AM. Imaging biomarkers of breast cancers originating from the major lactiferous ducts: Ductal adenocarcinoma of the breast, DAB. *Eur J Radiol*. 2022 Sep;154:110394. doi: 10.1016/j.ejrad.2022.110394. PMID: 35751940

Thomas CE, Dahl L, Byström S, Chen Y, Uhlén M, Mälarstig A, Czene K, Hall P, Schwenk JM, Gabrielson M. Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer. *Transl Oncol*. 2022 Jan 13;17:101339. doi: 10.1016/j.tranon.2022.101339.

Tran TV, Rubino C, Allodji R, Andruccioli M, Bardet S, Diallo I, Dottorini M, Garsi J, Hall P, Henry-Amar M, Lamart S, Le Thai F, Lönn S, Ricard M, Schwartz C, Schlumberger M, Journy N, de Vathaire F. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment. *Br J Cancer*. 2022 Oct 12. doi: 10.1038/s41416-022-01982-5.

Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Lindstrom LS, Vallon-Christersson J, Borg A, Hall P and Czene K. Interval breast cancer is associated with interferon immune response. *Eur J Cancer* 2022 Feb;162:194-205. doi: 10.1016/j.ejca.2021.12.003. PMID: 35026490

Veličković K, Borrebaeck CA, Bendahl PO, Hegardt C, Johnsson P, Richter C, Lisa Ryden L, Rahm Hallberg I. One-Year Recovery from Breast Cancer: Importance of Tumor and Treatment-Related Factors, Resilience, and Socio-Demographic Factors for Health-Related Quality of Life. *Front Oncol* 2022 Aug 16;12:891850. PMID: 36052232 doi: 10.3389/fonc.2022.891850.

Vikhe Patil E, Shabo I, Gimm O, Arnesson L-G, Fohlin H. Prediction of Non-Sentinel Node Metastasis in Breast Cancer –A Population-Based Study. *Advances in Cancer research & Clinical Imaging*, 2022 March DOI: 10.33552/ACRCI.2022.03.000565

Wadsten C, Wennstig AK, Garmo H, Lambe M, Blomqvist C, Holmberg L, Nilsson G, Wärnberg F, Fredriksson I, Sund M. Data Resource Profile: Breast Cancer Data Base Sweden 2.0 (BCBaSe 2.0). *Int J Epidemiol.* 2022 Jan 6;50(6):1770-1771f. doi: 10.1093/ije/dyab139. PMID: 34999855

Wang X, Kapoor PM, Auer PL, Dennis J, Dunning AM, Wang Q, Lush M, Michailidou K, Bolla MK, Aronson KJ, et al. Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. *Sci Rep.* 2022 Apr 13;12(1):6199. doi: 10.1038/s41598-022-10121-2.

Wang X, Chen H, Middha Kapoor P, Su YR, Bolla MK, Dennis J, Dunning AM, Lush M, Wang Q, Michailidou K, et al. A genome-wide gene-based gene-environment interaction study of breast cancer in more than 90,000 women. *Cancer Res Commun.* 2022 Apr;2(4):211-219. doi: 10.1158/2767-9764.CRC-21-0119.

Wang Y, Acs B, Robertson S, Liu B, Solorzano L, Wählby C, Hartman J, Rantalainen M. Improved breast cancer histological grading using deep learning. *Ann Oncol.* 2022 Jan;33(1):89-98. doi: 10.1016/j.annonc.2021.09.007. PMID: 34756513

Wennstig AK, Garmo H, Wadsten L, Lagerqvist B, Fredriksson I, Holmberg L, Blomqvist C, Nilsson G, Sund M. Risk of coronary stenosis after adjuvant radiotherapy for breast cancer. *Strahlenther Onkol.* 2022 Jul;198(7):630-638. doi: 10.1007/s00066-022-01927-0. PMID: 35389076

Wettergren L, Eriksson LE, Bergström C, Hedman C, Ahlgren J, Smedby KE, Hellman K, Henriksson R, Lampic C. Prevalence and risk factors for sexual dysfunction in young women following a cancer diagnosis - a population-based study. *Acta Oncol.* 2022 Oct;61(10):1165-1172. doi: 10.1080/0284186X.2022.2112283. Epub 2022 Sep 29. PMID: 36176069

Yang H, Bhoo-Pathy N, Brand JS, Hedayati E, Grassmann F, Zeng E, Bergh J, Bian W, Ludvigsson JF, Hall P, Czene K. Risk of heart disease following treatment for breast cancer - results from a population-based cohort study. *Elife.* 2022 Mar 16;11:e71562. doi: 10.7554/eLife.71562. PMID: 35293856

Yang X, Eriksson M, Czene K, Lee A, Leslie G, Lush M, Wang J, Dennis J, Dorling L, Carvalho S, Mavaddat N, Simard J, Schmidt MK, Easton DF, Hall P, Antoniou AC. Prospective validation

of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. *J Med Genet.* 2022 Sep 26;jmg-2022-108806. doi: 10.1136/jmg-2022-108806.

Zeng E, He W, Smedby KE, Czene K. Adjuvant Hormone Therapy-Related Hot Flashes Predict Treatment Discontinuation and Worse Breast Cancer Prognosis. *J Natl Compr Canc Netw.* 2022 Apr 6;20(6):683-689.e2. doi: 10.6004/jnccn.2021.7116.PMID: 35385829

Zeng E, He W, Sjolander A, Bergqvist J, Czene K. Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer. *Cancer Research.* 2022;82(19):3614-21.

2021

Acs B*, Fredriksson I*, Rönnlund C, Hagerling C, Ehinger A, Kovács A, Röge R, Bergh J, Hartman J. Variability in breast cancer biomarker assessment and the effect on oncological treatment decisions: A nationwide 5-year population-based study. *Cancers* 2021 Mar 9;13(5):1166. PMID:33803148

Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Bosch Campos A, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Johan Staaf J. Molecular analyses of triple-negative breast cancer in the young and elderly. *Breast Cancer Research* 2021 Feb 10;23(1):20. doi: 10.1186/s13058-021-01392-0. PMID: 33568222

André C, Holsti C, Svenner A, Sackey H, Oikonomou I, Appelgren M, Johansson ALV, de Boniface J. Oncoplastic breast-conserving surgery offers low local recurrence rates and excellent survival rates despite worse tumour characteristics. *BJS Open.* 2021, 5(1) DOI: 10.1093/bjsopen/zraa013. PMID: 33609387

Azam S, Eriksson M, Sjolander A, Gabrielson M, Hellgren R, Czene K, Hall P. Predictors of mammographic microcalcifications. *Int J Cancer.* 2021 Mar 1;148(5):1132-1143. doi: 10.1002/ijc.33302. PMID: 32949149

Azam S, Eriksson M, Sjolander A, Gabrielson M, Hellgren R, Czene K, Hall P. Mammographic microcalcifications and risk of breast cancer. *Br J of Cancer* 2021;125(5):759-65. doi: 10.1038/s41416-021-01459-x.

Baxter JS, Johnson N, Tomczyk K, Gillespie A, et al. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *Am J Hum Genet* 2021 Jul 1;108(7):1190-1203. doi: 10.1016/j.ajhg.2021.05.013. PMID: 34146516

Cieśła M, Ngoc PCT, Cordero E, Martinez S, Morsing M, Muthukumar S, Beneventi G, Madej M, Munita R, Jönsson T, Lövgren K, Ebbesson A, Nodin B, Hedenfalk I, Jirström K, Vallon-Christersson J, Honeth G, Staaf J, Incarnato D, Pietras K, Bosch A, Bellodi C. Oncogenic translation directs spliceosome dynamics revealing an integral role for SF3A3 in breast cancer. *Mol Cell.* 2021 Feb 26:S1097-2765(21)00054-X. doi: 10.1016/j.molcel.2021.01.034. PMID: 33662273

Coignard J, Lush M, Beesley J, O'Mara TA, et al. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nat Commun* 2021 Feb 17;12(1):1078. doi: 10.1038/s41467-020-20496-3. PMID: 33597508

Dahlgren M, George AM, Brueffer C, Gladchuk S, Chen Y, Vallon-Christersson J, Hegardt C, Häkkinen J, Rydén L, Malmberg M, Larsson C, Gruvberger-Saal SK, Ehinger A, Loman N, Borg Å, Saal LH. Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer. *JNCI Cancer Spectr.* 2021 Apr 22;5(2):pkab028. doi:10.1093/jncics/pkab028. PMID: 33937624

Dar H, Johansson A, Nordenskjöld A, Iftimi A, Yau C, Perez-Tenorio G, Benz C, Nordenskjöld B, Stål O, Esserman LJ, Fornander T, Lindström LS. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial. *JAMA Netw Open.* 2021 Jun 1;4(6):e2114904. doi: 10.1001/jamanetworkopen.2021.14904. PMID: 34190995

de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation versus mastectomy adjusted for comorbidity and socioeconomic status: national 6-year follow-up on 48986 women. *JAMA Surgery* 2021 Jul 1;156(7):628-637. doi: 10.1001/jamasurg.2021.1438. PMID: 33950173

Demircan K, Bengtsson Y, Sun Q, Brange A, Vallon-Christersson J, Rijntjes E, Malmberg M, Saal LH, Rydén L, Borg Å, Manjer J, Schomburg L. Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: A multicentre cohort study. *Redox Biol* 2021 Nov;47:102145. doi: 10.1016/j.redox.2021.102145. PMID: 34563873

Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, Pooley KA, Parsons MT, Fortuno C, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *N Engl J Med.* 2021;384(5):428-39. doi: 10.1056/NEJMoa1913948. PMID: 33471991

Eidemüller M, Holmberg E, Lundell M, Karlsson P. Evidence for Increased Susceptibility to Breast Cancer From Exposure to Ionizing Radiation Due to Familial History of Breast Cancer: Results From the Swedish Hemangioma Cohort. *Am J Epidemiol.* 2021 Jan 4;190(1):76-84. doi: 10.1093/aje/kwaa163. PMID: 3273501

Eriksson M, Czene K, Conant EF, Hall P. Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women. *Cancers (Basel).* 2021 Jan 15;13(2):E302. doi: 10.3390/cancers13020302. PMID: 33467653.

Escala-Garcia M, Canisius S, Keeman R, Beesley J, et al.. Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. *Sci Rep* 2021 Oct 5;11(1):19787. doi: 10.1038/s41598-021-99409-3. PMID: 34611289

Fredriksson A, Rosenberg E, Einbeigi Z, Bergh C, Strandell A. Gonadotrophin stimulation and risk of relapse in breast cancer. *Hum Reprod Open.* 2021 Jan 16;2021(1):hoaa061. doi: 10.1093/hropen/hoaa061. eCollection 2021. PMID: 33501382

Gedeborg R, Sund M, Lambe M, Plym A, Fredriksson I, Syrjä J, Holmberg L, Robinson D, Stattin P, Garmo H. (2021): An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate Cohorts. *Epidemiology* 32:607-615. 2021 Jul 1;32(4):607-615. doi: 10.1097/EDE.0000000000001358. PMID: 33935137

Gernaat SAM, Johnsson A, Altena R, Wilking U, Hedayati E. Sickness absence and disability pension among swedish women prior to breast cancer relapse with a special focus on the roles of treatment and comorbidity. *Eur J Cancer Care (Engl)*. 2021:e13353. doi: 10.1111/ecc.13353. PMID: 33151558

Grassmann F, Yang H, Eriksson M, Azam S, Hall P, Czene K. Mammographic features are associated with cardiometabolic disease risk and mortality. *Eur Heart J* 2021 Sep 7;42(34):3361-3370. doi: 10.1093/eurheartj/ehab502. PMID: 34338750

Gulis K, Rydén L, Bendahl PO, Svensjö T. Cosmetic Outcomes and Symmetry Comparison in Patients Undergoing Bilateral Therapeutic Mammoplasty for Breast Cancer. *World J of Surgery* 2021; 45 (5), 1433 – 1441.

Henriksson A, Johansson B, Radu C, Berntsen S, Igelström H, Nordin K. Is it safe to exercise during oncological treatment? A study of adverse events during endurance and resistance training - data from the Phys-Can study. *Acta Oncol*. 2021 Jan;60(1):96-105. doi: 10.1080/0284186X.2020.1851046. Epub 2020 Dec 18. PMID: 33339484

Holm J, Yu NY, Johansson A, Ploner A, Hall P, Lindstrom LS and Czene K. Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer. *JNCI Cancer Spectr* 2020 Oct 7;5(1):pkaa087. PMID: 33442660

Isheden G, Grassmann F, Czene K and Humphreys K. Lymph node metastases in breast cancer: Investigating associations with tumor characteristics, molecular subtypes and polygenic risk score using a continuous growth model. *Int J Cancer* 2021 Sep 15;149(6):1348-1357. doi: 10.1002/ijc.33704. PMID: 34097750

Isheden G, Czene K, Humphreys K. Random effects models of lymph node metastases in breast cancer: quantifying the roles of covariates and screening using a continuous growth model. *Biometrics*. 2021 Jan 26. doi: 10.1111/biom.13430. PMID: 33501643

Janeva S, Parris TZ, Nasic S, De Lara S, Larsson K, Audisio RA, Olofsson Bagge R, Kovács A. Comparison of breast cancer surrogate subtyping using a closed-system RT- qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens. *BMC Cancer*. 2021 Apr 21;21(1):439. PMID: 33879115

Jaraj D, Höijer J, Widman L, Ahlgren J, Arnesson LG, Einbeigi Z, Klintman M, Vikhe Patil E, Sund M, Fredriksson I*, Bergh J*, Pettersson A*. Long-term prognostication for 20 114 women with small and node-negative breast cancer (T1abN0). *JNCI Cancer Spectrum* 2021 Sep 26;5(1):pkaa084. PMID: 33442658

Johansson A, Christakou AE, Iftimi A, Eriksson M, Tapia J, Skoog L, Benz CC, Rodriguez-Wallberg KA, Hall P, Czene K and Lindstrom LS. Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. *J AMA Netw Open* 2021 Jun 1;4(6):e2114716. doi: 10.1001/jamanetworkopen.2021.14716. PMID: 34170304

Johnson N, Maguire S, Morra A, Kapoor PM, Tomczyk K, Jones ME, et al. CYP3A7*1C allele: linking premenopausal oestrogen and progesterone levels with risk of hormone receptor-positive breast cancers. *Br J Cancer* 2021 Feb;124(4):842-854. doi: 10.1038/s41416-020-01185-w. PMID: 33495599

Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindstrom S, et al. Combined associations of a polygenic risk score and classical risk factors with breast cancer risk. *J Natl Cancer Inst* 2021 Mar 1;113(3):329-337. doi: 10.1093/jnci/djaa056. PMID: 32359158

Klint L, Kovacs A, Rönnerman E, Linderholm B. Real world data on adjuvant treatment of older HER2-positive breast cancer patients – A single institution experience through 8 years. *Cancer Treat Res Commun* 2021;28:100430. doi: 10.1016/j.ctarc.2021.100430.

Majid S, Bendahl P-O, Huss L, Manjer J, Rydén L, Dihge L. Validation of the Skåne University Hospital nomogram for the preoperative prediction of a disease-free axilla in patients with breast cancer. *BJS Open* 2021; 5 (3) May 7th. *BJS Open* 2021 May 7;5(3):zrab027. doi: 10.1093/bjsopen/zrab027. PMID: 34157725

Marklund A, Lundberg FE, Eloranta S, Hedayati E, Pettersson K, Rodriguez-Wallberg KA. Reproductive Outcomes After Breast Cancer in Women With vs Without Fertility Preservation. *JAMA Oncol.* 2021 Jan 1;7(1):86-91. doi: 10.1001/jamaoncol.2020.5957. PMID: 33211089

Mohlin Å, Bendahl PO, Hegardt C, Richter C, Hallberg IR, Rydén L. Psychological resilience and health-related quality of life in 418 Swedish women with primary breast cancer: Results from a prospective longitudinal study. *Cancers* 2021 May 6;13(9):2233. doi:10.3390/cancers13092233. PMID: 34066499

Morra A, Escala-Garcia M, Beesley J, Keeman R, Canisius S, et al. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Res* 2021 Aug 18;23(1):86. doi: 10.1186/s13058-021-01450-7. PMID: 34407845

Morra A, Jung AY, Behrens S, Keeman R, Ahearn TU, Anton-Cluver H, et al. J. Breast cancer risk factors and survival by tumor subtype: pooled analyses from the Breast Cancer Association Consortium. *Cancer Epidemiol Biomarkers Prev* 2021 Apr;30(4):623-642. doi: 10.1158/1055-9965.EPI-20-0924. PMID: 33500318

Narbe U, Bendahl P-O, Fernö M, Ingvar C, Dihge L, Rydén L. St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study. *Br J Surg.* 2021 Dec 1;108(12):1465-1473. doi: 10.1093/bjs/znab327. PMID: 34636842

Ong JS, Derks EM, Eriksson M, An J, Hwang LD, Easton DF, Pharoah PP, Berchuck A, Kelemen LE, Matsuo K, Chenevix-Trench G, Hall P, Bojesen SE, Webb PM, MacGregor S. Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses. *Int J Cancer.* 2021 Sep 25. doi: 10.1002/ijc.33308. PMID: 32976626

Park HA, Neumeyer S, Michailidou K, Bolla MK, Wang Q, et al. Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *Br J Cancer* 2021 Oct;125(8):1135-1145. doi: 10.1038/s41416-021-01432-8. Epub 2021 Aug 2. PMID: 34341517

Park J, Choi JY, Choi J, Chung S, Song N, et al. Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies? *Cancers (Basel)* 2021 May 14;13(10):2370. doi: 10.3390/cancers13102370. PMID: 34069208

Sartor H, Zackrisson S, Hegardt C, Larsson C. Association of mammographic features with molecular breast tumor profiles. *Cancer Treat Res Commun.* 2021;28:100387. doi: 10.1016/j.ctarc.2021.100387. Epub 2021 May 9. PMID: 34004506

Schiza A, Mauri D, Fredriksson I, Wennstig A-K, Valachis A. Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study. *Breast Cancer Research and Treat* 2021 Apr;186(3):779-789. doi: 10.1007/s10549-020-06022-5. Epub 2020 Nov 30. PMID: 33258078

Sund M, Garcia-Argibay M, Garmo G, Ahlgren J, Wennstig A-K, Fredriksson I, Lindman H, Valachis A (2021): Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study. *Breast*; 59:157-164. PMID: 34265496.

Tabár L, Chen TH, Yen AM, Dean PB, Smith RA, Jonsson H, Törnberg S, Chen SL, Chiu SY, Fann JC, Ku MM, Wu WY, Hsu CY, Chen YC, Svane G, Azavedo E, Grundström H, Sundén P, Leifland K, Frodis E, Ramos J, Epstein B, Åkerlund A, Sundbom A, Bordás P, Wallin H, Starck L, Björkgren A, Carlson S, Fredriksson I, Ahlgren J, Öhman D, Holmberg L, Duffy SW. Early Detection of Breast Cancer Rectifies Early detection of breast cancer rectifies inequality of breast cancer outcomes. *J Med Screen.* 2021 May 5:969141320921210. PMID: 32370610.

Tan PS, Ali MA, Eriksson M, Hall P, Humphreys K, Czene K. Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics: A population-based cohort study. *Int J Cancer* 2021 Mar 15;148(6):1351-1359. doi:10.1002/ijc.33309. PMID: 32976625

Thorén L, Lindh JD, Ackehed G, Kringen MK, Hall P, Bergh J, Molden E, Margolin S, Eliasson E. Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. *Br J Clin Pharmacol.* 2021 Mar;87(3):1243-1252

Thorén L, Eriksson M, Lindh JD, Czene K, Bergh J, Eliasson E, Hall P, Margolin S. Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. *Breast Cancer Res Treat.* 2021 Dec;190(3):451-462.

Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Borg Å, Vallon-Christersson J, Hall P, Czene K. Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns. *Int J Cancer.* 2021 Feb 15;148(4):884-894. doi: 10.1002/ijc.33270. PMID: 32856720

Valachis A, Carlqvist P, Szilcz M, Freilich J, Vertuani S, Holm B, Lindman H. Use of classifiers to optimise the identification and characterisation of metastatic breast cancer in a nationwide administrative registry. *Acta Oncol.* 2021 Dec;60(12):1604-1610. doi: 10.1080/0284186X.2021.1979645. PMID: 34549678

Valachis A, Nyström P, Fredriksson I, Wennstig A-K, Ahlgren J. Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer. *J Geriatric Oncol* 2021 Mar; 12(2):212-218. PMID: 32928712

Wadsten C, Wennstig AK, Garmo H, Lambe M, Blomqvist C, Holmberg L, Nilsson G, Wärnberg F, Fredriksson I, Sund M. Data Resource Profile: Breast Cancer Data Base Sweden (BCBaSe 2.0). *Int J Epidemiol*. 2021, 1770–1771f doi: 10.1093/ije/dyab139. PMID: 34473274

Wang Y, Kartasalo K, Weitz P, Ács B, Valkonen M, Larsson C, Ruusuvaori P, Hartman J, Rantalainen M. Predicting Molecular Phenotypes from Histopathology Images: A Transcriptome-Wide Expression-Morphology Analysis in Breast Cancer. *Cancer Res*. 2021 Oct 1;81(19):5115-5126

Wennstig A-K, Wadsten C, Garmo H, Johansson M, Fredriksson I, Blomqvist C, Holmberg L, Nilsson G, Sund M. Risk of primary lung cancer after adjuvant radiotherapy in breast cancer - a large population-based study. *NPJ Breast Cancer* 2021 Jun 1;7(1):71. doi: 10.1038/s41523-021-00280-2. PMID: 34075042

Wide A, Wettergren L, Ahlgren J, Smedby KE, Hellman K, Henriksson R, Rodriguez-Wallberg K, Ståhl O, Lampic C. Fertility-related information received by young women and men with cancer - a population-based survey. *Acta Oncol*. 2021 Aug;60(8):976-983. doi: 10.1080/0284186X.2021.1900909. Epub 2021 Mar 25. PMID: 33764839

Zerdes I, Karafousia V, Mezheyski A, Stogiannitsi M, Kuiper R, Moreno Ruiz P, Rassidakis G, Bergh J, Hatschek T, Foukakis T, Matikas A. Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer. *Cancers (Basel)*. 2021 Sep 16;13(18):4655. doi: 10.3390/cancers13184655. PMID: 34572882

2020

Agustsson AS, Birgisson H, Agnarsson BA, Jonsson T, Stefansdottir H, Wärnberg F, Lambe M, Tryggvadottir L, Sverrisdottir A. In situ breast cancer incidence patterns in Iceland and differences in ductal carcinoma in situ treatment compared to Sweden. *Sci Rep*. 2020 Oct 19;10(1):17623. doi: 10.1038/s41598-020-74134-5. PMID: 33077767

Aurin J, Thorlacius H, Butt ST. Age at first childbirth and breast **cancer** survival: a prospective cohort **study**. *BMC Res Notes*. 2020 Jan 6;13(1):9. doi: 10.1186/s13104-019-4864-1. PMID: 31907014

Azam S, Eriksson M, Sjölander A, Hellgren R, Gabrielson M, Czene K, Hall P. Mammographic Density Change and Risk of Breast Cancer. *J Natl Cancer Inst*. 2020 Apr 1;112(4):391-399. doi: 10.1093/jnci/djz149. PMID: 31298705.

Bergqvist M, Elebro K, Sandsveden M, Borgquist S, Rosendahl AH. Effects of tumor-specific CAP1 expression and body constitution on clinical outcomes in patients with early breast cancer. *Breast Cancer Res*. 2020 Jun 19;22(1):67. doi: 10.1186/s13058-020-01307-5. PMID: 32560703

Bjarnadottir O, Feldt M, Inasu M, Bendahl PO, Elebro K, Kimbung S, Borgquist S. Statin use, HMGCR expression, and breast cancer survival - The Malmo Diet and Cancer Study. *Sci Rep*. 2020 Jan 17;10(1):558. doi: 10.1038/s41598-019-57323-9. PMID: 31953433

de Boniface J, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, Olofsson Bagge R, Rydén L, Sund M on behalf of the SENOMAC Trialists' Group. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer. *Breast Cancer Res Treat* 2020, 180(1): 167-176. doi: 10.1007/s10549-020-05537-1 PMID: 31989379

Brueffer C, Gladchuk S, Winter C, Vallon-Christersson J, Hegardt C, Häkkinen J, George AM, Chen Y, Ehinger A, Larsson C, Loman N, Malmberg M, Rydén L, Borg Å, Saal LH. The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome. *EMBO Mol Med*. 2020 12:e12118. doi: 10.15252/emmm.202012118. PMID: 32926574

Duffy SW, Tabar L, Yen A M-F, Dean PB, Smith RA, Jonsson H, Törnberg S, Chen SL-S, Chiu SY-H, Fann JC-Y, Ku MM-S, Wu WY-Y, Hsu C-Y, Chen Y-Y, Svane G, Azavedo E, Grundström H, Sundén P, Leifland K, Frodis E, Ramos J, Epstein B, Åkerlund A, Sundbom A, Bordás P, Wallin H, Starck L, Björkgren A, Carlsson S, Fredriksson I, Ahlgren J, Öhman D, Holmberg L, Chen TH-H. Mammography screening reduces rates of advanced and fatal breast cancers: results in 549,091 women. *Cancer* 2020 Jul 1;126(13):2971-2979. PMID: 32390151

Edman Kessler L, Sigfridsson J, Hatzidaki D, Bergh J, Foukakis T, Georgoulas V, Matikas A. Chemotherapy use near the end-of-life in patients with metastatic breast cancer. *Breast Cancer Res Treat*. 2020 Jun;181(3):645-651. doi: 10.1007/s10549-020-05663-w. PMID: 32383058

Enlund M, Berglund A, Ahlstrand R, Walldén J, Lundberg J, Wärnberg F, Ekman A, Sjöblom Widfeldt N, Enlund A, Bergkvist L. Survival after primary breast cancer surgery following propofol or sevoflurane general anesthesia-A retrospective, multicenter, database analysis of 6305 Swedish patients. *Acta Anaesthesiol Scand*. 2020 Sep;64(8):1048-1054. doi: 10.1111/aas.13644. Epub 2020 Jun 10. PMID: 32415980.

Eriksson M, Czene K, Strand F, Zackrisson S, Lindholm P, Lång K, Förnvik D, Sartor H, Mavaddat N, Easton D, Hall P. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. *Radiology*. 2020 Sep 8;201620. doi: 10.1148/radiol.2020201620. PMID: 32897160

Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, Auvinen P, Beckmann MW, Beesley J, et al. A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nat Commun*. 2020 Jan 16;11(1):312. doi: 10.1038/s41467-019-14100-6. PMID: 31911677

Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nat Genet*. 2020 Jan;52(1):56-73. doi: 10.1038/s41588-019-0537-1. PMID: 31911677

Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-Full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, et al. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genet Epidemiol*. 2020 Mar 1. doi: 10.1002/gepi.22288. PMID: 32115800.

Frisell A, Lagergren J, Halle M, de Boniface J. Socioeconomic status influences immediate breast reconstruction rates, patient information and involvement in surgical decision-making. *BJS Open* 2020, Jan 31. doi: 10.1002/bjs5.50260. PMID: 32003544

Giardiello D, Hauptmann M, Steyerberg EW, Adank MA, Akdeniz D, Blom JC, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, et al. Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. *Breast Cancer Res Treat.* 2020 Apr 11. doi: 10.1007/s10549-020-05611-8. PMID: 32279280.

Gisladottir LD, Birgisson H, Agnarsson BA, Jonsson T, Tryggvadottir L, Sverrisdottir A. [Comparison of diagnosis and treatment of invasive breast cancer between Iceland and Sweden]. *Laeknabladid.* 2020 Sep;106(9):397-402. doi: 10.17992/lbl.2020.09.595.PMID: 32902398

Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. *Nat Commun.* 2020 Jul 27;11(1):3747. doi: 10.1038/s41467-020-17537-2. PMID: 32719340

He W, Grassmann F, Eriksson M, Eliasson E, Margolin S, Thorén L, Hall P, Czene K. CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. *J Clin Oncol.* 2020. Feb 20;38(6):548-557. doi: 10.1200/JCO.19.01535.PMID: 31800347.

Hellgren R, Saracco A, Strand F, Eriksson M, Sundbom A, Hall P, Dickman PW. The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI. *Acta Radiol.* 2020 Mar 26:284185120911583. doi: 10.1177/0284185120911583. PMID:32216451

Holowko N, Eriksson M, Kuja-Halkola R, Azam S, He W, Hall P, Czene K. Heritability of Mammographic Breast Density, Density Change, Microcalcifications, and Masses. *Cancer Res.* 2020 Apr 1;80(7):1590-1600. doi: 10.1158/0008-5472.CAN-19-2455. PMID:32241951.

Houvenaeghel G, El Hajj H, Barrou J, Cohen M, Raro P, De Troyer J, Gimbergues P, Tunon de Lara C, Ceccato V, Vaini-Cowen V, et al; The Serc Trial Group. External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis. *Cancers (Basel).* 2020 Oct 11;12(10):2924. doi: 10.3390/cancers12102924.PMID: 33050650.

Hu K, Eriksson M, Wengström Y, Czene K, Hall P, Fang F. Sense of coherence and risk of breast cancer. *Elife.* 2020 Nov 23;9:e61469. doi: 10.7554/eLife.61469. PMID: 33226344.

Ingvar C, Ahlgren J, Emdin S, Lofgren L, Nordander M, Niméus E, Arnesson LG. Long-term outcome of pT1a-b, cN0 breast cancer without axillary dissection or staging: a prospective observational study of 1543 women. *Br J Surg.* 2020 Sep;107(10):1299-1306. doi: 10.1002/bjs.11610. Epub 2020 Apr 26. PMID: 32335901

Janeva S, Zhang C, Kovacs A, Parris T, Crozier JA, Pezzi CM, Linderholm B, Audisio RA, Olofsson Bagge R. Adjuvant chemotherapy and survival in women aged 70 years and older

with triple-negative breast cancer: a Swedish population-based propensity score-matched analysis. *The Lancet Healthy Longevity*. 2020 Dec 1;1(3) E117-E124 (ingen PMID).

Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, Michailidou K, Dennis J, Bolla MK, Wang Q, et al. Combined associations of a polygenic risk score and classical risk factors with breast cancer risk. *J Natl Cancer Inst*. 2020 May 2:djaa056. doi: 10.1093/jnci/djaa056. PMID: 32359158.

Kramer I, Hooning MJ, Mavaddat N, Hauptmann M, Keeman R, Steyerberg EW, Giardiello D, Antoniou AC, Pharoah PDP, Canisius S, et al. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *Am J Hum Genet*. 2020 Sep 28:S0002-9297(20)30321-9. doi: 10.1016/j.ajhg.2020.09.001. PMID: 33022221

Larsson C, Ehinger A, Winslow S, Leandersson K, Klintman M, Dahl L, Vallon-Christersson J, Häkkinen J, Hegardt C, Manjer J, Saal L, Rydén L, Malmberg M, Borg Å, Loman N. Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. *NPJ Breast Cancer*. 2020 Jul 6;6:28. doi: 10.1038/s41523-020-0170-2. PMID: 32656317

Liu J, Prager-van der Smissem WJC, Collée JM, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB, et al. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Sci Rep*. 2020 Jun 16;10(1):9688. doi: 10.1038/s41598-020-65665-y. PMID: 32546843.

Mohlin Å, Axelsson U, Bendahl PO, Borrebaeck C, Hegardt C, Johnsson P, Rahm Hallberg I, Rydén L. Psychological Resilience and Health-Related Quality of Life in Swedish Women with Newly Diagnosed Breast Cancer. *Cancer Manag Res*. 2020 Nov 24;12:12041-12051. doi: 10.2147/CMAR.S268774. eCollection 2020. PMID: 33269004

Persson H, Søkilde R, Häkkinen J, Vallon-Christersson J, Mitelman F, Borg Å, Höglund M, Rovira C. Analysis of fusion transcripts indicates widespread deregulation of snoRNAs and their host genes in breast cancer. *Int J Cancer*. 2020 Jun 15;146(12):3343-3353. doi: 10.1002/ijc.32927. PMID: 32067223

Plym A, Johansson ALV, Bower H, Wennstig AK, Fredriksson I, Ahlgren J, Lambe M. Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study. *Breast Cancer Res Treat*. 2020 Aug;182(3):699-707. PMID: 32506337

Rainey L, Eriksson M, Trinh T, et al. The impact of alcohol consumption and physical activity on breast cancer: The role of breast cancer risk. *Int J Cancer*. 2020 Aug 15;147(4):931-939. doi: 10.1002/ijc.32846. PMID: 31863475

Sturesdotter L, Sandsveden M, Johnson K, Larsson AM, Zackrisson S, Sartor H. Mammographic tumour appearance is related to clinicopathological factors and surrogate molecular breast cancer subtype. *Sci Rep*. 2020 Nov 30;10(1):20814. doi: 10.1038/s41598-020-77053-7. PMID: 33257731

Sundén M, Hermansson C, Taflin H, Andersson A, Sund M, Hemmingsson O. Surgical treatment of breast cancer liver metastases - A nationwide registry-based case control study. *Eur J Surg Oncol*. 2020 Jun;46(6):1006-1012. doi: 10.1016/j.ejso.2020.02.008. PMID: 32098734

Ullgren H, Sharp L, Olofsson A, Fransson P. Factors associated with healthcare utilisation during first year after cancer diagnose-a population-based study. *Eur J Cancer Care (Engl)*. 2021 Mar;30(2):e13361. doi: 10.1111/ecc.13361. Epub 2020 Nov 20. PMID: 33216423

Unukovych D, Gümüşcü R, Wärnberg F, de Boniface J, Eriksen C, Sund M, Näsell P, Åhsberg K, Olofsson P, Lewin R, Lambe M, Brandberg Y, Folkvaljon F, Mani M. Breast reconstruction patterns from a Swedish nation-wide survey. *European Journal of Surgical Oncology*. 2020, doi:10.1016/j.ejso.2020.04.030 PMID:32698944

Valachis A, Garmo H, Fredriksson I, Sund M, Lagerqvist B, Holmberg L. Bleeding risk in breast cancer patients during concomitant administration of warfarin and tamoxifen: A population-based nested case-control study. *Breast J*. 2020 May;26(5):981-987. PMID:31989762

Wennstig A-K, Wadsten C, Garmo H, Fredriksson I, Blomqvist C, Holmberg L, Nilsson G, Sund M. Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer – results from a large population-based cohort. *Breast Cancer Res* 2020 Jan 22;22(1):10. PMID:31969169

Wettergren L, Ljungman L, Micaux Obol C, Eriksson LE, Lampic C. Sexual dysfunction and fertility-related distress in young adults with cancer over 5 years following diagnosis: study protocol of the Fex-Can Cohort study. *BMC Cancer*. 2020 Aug 5;20(1):722. doi: 10.1186/s12885-020-07175-8. PMID: 32758179

Yang H, Holowko N, Grassmann F, Eriksson M, Hall P, Czene K. Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors. *BMC Med*. 2020;18(1):225. doi: 10.1186/s12916-020-01690-y. PMID: 32838791

Zerdes I, Sifakis EG, Matikas A, Chrétien S, Tobin NP, Hartman J, Rassidakis GZ, Bergh J, Foukakis T. Programmed Death Ligand-1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. *Molecular Oncology* 14:951-963, 2020.

Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nat Genet*. 2020 May 18. doi: 10.1038/s41588-020-0609-2. PMID: 32424353.

2019

Alsheh Ali M, Eriksson M, Czene K, Hall P, Humphreys K. Detection of Potential Microcalcification Clusters Using Multivendor For-presentation Digital Mammograms for Short-term Breast Cancer Risk estimation. *Med Phys*. 2019 Feb 23. doi: 10.1002/mp.13450. PMID: 30801718.

Alsheh Ali M, Czene K, Hall P, Humphreys K. Association of Microcalcification Clusters with Short-term Invasive Breast Cancer Risk and Breast Cancer Risk Factors. *Sci Rep.* 2019 Oct 10;9(1):14604. doi: 10.1038/s41598-019-51186-w. PMID: 31601987.

Andersson Y, Bergkvist L, Frisell J et al. Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer. *Breast cancer research and treatment.* 2019;177(2):469-75. PMID: 31236811

Bjöhle J, Onjukka E, Rintelä N, Eloranta S, Wickman M, Sandelin K, Gagliardi G, Liljegren A. Post-mastectomy radiation therapy with or without implant-based reconstruction is safe in terms of clinical target volume coverage and survival - A matched cohort study. *Radiother Oncol.* 2019 Feb;131:229-236. doi: 10.1016/j.radonc.2018.07.005. Epub 2018 Jul 25. PMID: 30055939

Bower H, Andersson TM, Syriopoulou E et al. Potential gain in life years for Swedish women with breast cancer if stage and survival differences between education groups could be eliminated - Three what-if scenarios. *Breast.* 2019 Jun;45:75-81. doi: 10.1016/j.breast.2019.03.005. PMID: 30904700

Dihge L, Vallon-Christersson J, Hegardt C et al. Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort. *Clin Cancer Res.* 2019 Nov 1;25(21):6368-6381. doi: 10.1158/1078-0432.CCR-19-0075 PMID: 31340938

Dörk T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, et al. Two truncating variants in FANCC and breast cancer risk. *Sci Rep.* 2019 Aug 29;9(1):12524. doi: 10.1038/s41598-019-48804-y. PMID: 31467304.

Eriksson L, He W, Eriksson M et al. Adjuvant Therapy and Mammographic Density Changes in Women With Breast Cancer. *JNCI Cancer Spectr.* 2019 Jan 29;2(4):pky071. doi: 10.1093/jncics/pky071. PMID:31360886

Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, et al. Genome-wide association study of germline variants and breast cancer-specific mortality. *Br J Cancer.* 2019 Feb 21. doi: 10.1038/s41416-019-0393-x. PMID: 30787463.

Ferreira MA, Gamazon ER, Al-Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, et al. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nat Commun.* 2019 Apr 15;10(1):1741. doi: 10.1038/s41467-018-08053-5. PMID: 30988301.

Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, et al. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *NPJ Breast Cancer.* 2019 Nov 1;5:38. doi: 10.1038/s41523-019-0127-5. PMID: 31700994.

Förnvik D, Aaltonen KE, Chen Y, George AM, Brueffer C, Rigo R, Loman N, Saal LH, Rydén L. Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for

neoadjuvant treatment. *Breast Cancer Res Treat.* 2019 Sep;177(2):447-455. doi: 10.1007/s10549-019-05326-5. PMID: 31236809

Garvin S, Vikhe Patil E, Arnesson LG, Oda H, Hedayati E, Lindström A, Shabo I. Differences in intra-tumoral macrophage infiltration and radiotherapy response among intrinsic subtypes in pT1-T2 breast cancers treated with breast-conserving surgery. *Virchows Arch.* 2019 Aug;475(2):151-162. doi: 10.1007/s00428-019-02563-3. PMID: 30915533.

Giardiello D, Steyerberg EW, Hauptmann M, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, et al. Prediction and clinical utility of a contralateral breast cancer risk model. *Breast Cancer Res.* 2019 Dec 17;21(1):144. doi: 10.1186/s13058-019-1221-1. PMID: 31847907

Grassmann F, He W, Eriksson M, Gabrielson M, Hall P, Czene K. Interval breast cancer is associated with other types of tumors. *Nat Commun.* 2019 Oct 22;10(1):4648. doi: 10.1038/s41467-019-12652-1. PMID: 31641120.

He W, Eriksson L, Törnberg S et al. Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening. *BMC Med.* 2019 Jan 31;17(1):24. doi: 10.1186/s12916-019-1252-6. PMID: 30700300

Hersi AF, Eriksson S, Ramos J, Abdsaleh S, Warnberg F, Karakatsanis A. A combined, totally magnetic technique with a magnetic marker for non-palpable tumour localization and superparamagnetic iron oxide nanoparticles for sentinel lymph node detection in breast cancer surgery. *European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.* 2019;45(4):544-9. PMID: 30401506

Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesueur C, Kuchenbaecker KB, Dennis J, et al. Shared heritability and functional enrichment across six solid cancers. *Nat Commun.* 2019 Jan 25;10(1):431. doi: 10.1038/s41467-018-08054-4. PMID: 30683880.

Johansson ALV, Weibull CE, Fredriksson I et al. Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact. *Breast Cancer Res Treat.* 2019 Apr;174(2):489-503. PMID:30552644

Johnson K, Zackrisson S, Rosso A et al. Tumor Characteristics and Molecular Subtypes in Breast Cancer Screening with Digital Breast Tomosynthesis: The Malmö Breast Tomosynthesis Screening Trial. *Radiology.* 2019 Nov;293(2):273-281. doi: 10.1148/radiol.2019190132. PMID:31478799

Karakatsanis A, Hersi AF, Pistiolis L, Olofsson Bagge R, Lykoudis PM, Eriksson S, et al. Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). *The British journal of surgery.* 2019;106(6):720-8. PMID: 30839104

Karlsson A, Gonzalez V, Jaraj SJ, Bottai M, Sandelin K, Arver B, et al. The accuracy of incremental pre-operative breast MRI findings - Concordance with histopathology in the Swedish

randomized multicenter POMB trial. *European journal of radiology*. 2019;114:185-91. PMID: 31005171

Li J, Wen WX, Eklund M et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. *Int J Cancer*. 2019 Mar 1;144(5):1195-1204. doi: 10.1002/ijc.31841. PMID: 30175445

Löfgren L, Eloranta S, Krawiec K, Asterkvist A, Lönnqvist C, Sandelin K. Validation of data quality in the Swedish National Register for Breast Cancer. *BMC Public Health* 2019;19(1):495. PMID: 31046737

Lundberg A, Lindström LS, Li J, Harrell JC, Darai-Ramqvist E, Sifakis EG, Foukakis T, Perou CM, Czene K, Bergh J, Tobin NP. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. *Breast Cancer Res*. 2019 Feb 28;21(1):34. doi: 10.1186/s13058-019-1121-4. PMID: 30819233.

Lundgren C, Bendahl PO, Borg Å, Ehinger A, Hegardt C, Larsson C, Loman N, Malmberg M, Olofsson H, Saal LH, Sjöblom T, Lindman H, Klintman M, Häkkinen J, Vallon-Christersson J, Fernö M, Rydén L, Ekholm M. Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. *Breast Cancer Res Treat*. 2019 Aug 20. doi: 10.1007/s10549-019-05378-7. PMID: 31432367

Majid S, Rydén L, Manjer J. Determinants for non-sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 602 consecutive patients with sentinel node metastases. *BMC Cancer* 2019 Jun 25;19(1):626. doi: 10.1186/s12885-019-5823-x. PMID:31238899.

Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *Am J Hum Genet*. 2019 Jan 3;104(1):21-34. doi: 10.1016/j.ajhg.2018.11.002. PMID: 30554720

Myndigheten för vård- och omsorgsanalys, 2019. Rapport 2019:8. Omotiverat olika Socioekonomiska och regionala skillnader i cancervården.

Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N. High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study. *Breast Cancer Res Treat* 2019 Jan;173(2):313-318. PMID: 30311024

Nilsson MP, Nilsson ED, Silfverberg B, Borg Å, Loman N. Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake. *Genet Med*. 2019 Jan;21(1):89-96. PMID: 29875420

Nordenskjöld AE, Fohlin H, Arnesson LG et al. Breast cancer survival trends in different stages and age groups - a population-based study 1989-2013. *Acta Oncol* 2019 Jan;58(1):45-51. doi: 10.1080/0284186X.2018.1532601. PMID: 30513223

Ooi BNS, Loh H, Ho PJ, Milne RL, Giles G, Gao C, Kraft P, John EM, Swerdlow A, Brenner H, Wu AH, Haiman C, Evans DG, Zheng W, Fasching PA, Castela JE, Kwong A, Shen X, Czene K, Hall P, Dunning A, Easton D, Hartman M, Li J. The genetic interplay between body

mass index, breast size and breast cancer risk: a Mendelian randomization analysis. *Int J Epidemiol* 2019 Jun 1;48(3):781-794. doi: 10.1093/ije/dyz124. PMID: 31243447.

Plym A, Johansson ALV, Bower H, et al. Causes of sick leave, disability pension and death following a breast cancer diagnosis in women of working age. *Breast*. 2019 Jun;45:48-55. PMID:30852409.

Rosenberg E, Fredriksson A, Einbeigi Z, Bergh C, Strandell A. No increased risk of relapse of breast cancer for women who give birth after assisted conception. *Hum Reprod Open*. 2019 Dec 18;2019(4):hoz039. doi: 10.1093/hropen/hoz039. eCollection 2019. PMID: 31872070

Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S. Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. *Nat Med* 2019;25:1526-33 PMID: 31570822

Stenmark Tullberg A, Lundstedt D, Olofsson Bagge R et al. Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy? *Acta Oncol*. 2019 Feb;58(2):162-167. doi: 10.1080/0284186X.2018.1533647. PMID: 30407093

Strand F, Azavedo E, Hellgren R, et al. Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study. *Breast Cancer Res*. 2019 Jan 22;21(1):8. doi: 10.1186/s13058-019-1099-y. PMID:30670066.

Strell C, Paulsson J, Jin SB, Tobin NP, Mezheyeuski A, Roswall P, et al. Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ. *J Natl Cancer Inst* 2019;111(9):983-95. PMID: 30816935

Søkilde R, Persson H, Ehinger A, Pirona AC, Fernö M, Hegardt C, Larsson C, Loman N, Malmberg M, Rydén L, Saal L, Borg Å, Vallon-Christerson J, Rovira C. Refinement of breast cancer molecular classification by miRNA expression profiles. *BMC Genomics* 2019 20(1):503. doi: 10.1186/s12864-019-5887-7. PMID: 31208318

Vachon CM, Scott CG, Tamimi RM, Thompson DJ, Fasching PA, Stone J, Southey MC, Winham S, Lindström S, Lilyquist J, et al. Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. *Breast Cancer Res* 2019 May 22;21(1):68. doi: 10.1186/s13058-019-1138-8. PMID: 31118087.

Vallon-Christersson J, Häkkinen J, Hegardt C, Saal LH, Larsson C, Ehinger A, Lindman H, Olofsson H, Sjöblom T, Wärnberg F, Ryden L, Loman N, Malmberg M, Borg Å, Staaf J. Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. *Sci Rep*. 2019 Aug 21;9(1):12184. doi: 10.1038/s41598-019-48570-x. PMID: 31434940

Wärnberg F, Stigberg E, Obondo C et al. Long-Term Outcome After Retro-Areolar Versus Peri-Tumoral Injection of Superparamagnetic Iron Oxide Nanoparticles (SPIO) for Sentinel Lymph Node Detection in Breast Cancer Surgery. *Annals of surgical oncology*. 2019;26(5):1247-53. PMID: 30830536

Wennstig AK, Garmo H, Isacson U et al. The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors. *Radiat Oncol*. 2019 Mar 7;14(1):40. doi: 10.1186/s13014-019-1242-z. PMID: 30845947

Yu NY, Iftimi A, Yau C et al. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. *JAMA Oncol*. 2019 Aug 8. doi: 10.1001/jamaoncol.2019.1856. PMID: 31393518

Öfverholm A, Einbeigi Z, Wigermo A, Holmberg E, Karlsson P. Increased Overall Mortality Even after Risk Reducing Surgery for *BRC*A-Positive Women in Western Sweden. *Genes (Basel)*. 2019 Dec 16;10(12):1046. doi: 10.3390/genes10121046. PMID: 31888263

2018

Adam H, Docherty Skogh AC, Edsander Nord Å, Schultz I, Gahm J, Hall P, Frisell J, Halle M, de Boniface J. Risk of recurrence and death in breast cancer patients after delayed deep inferior epigastric perforator flap reconstruction. *Br J Surg* 2018, 105(11):1435-1445. PMID: 29683203

Andersson Y, Bergkvist L, Frisell J, de Boniface J. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. *Breast cancer research and treatment*. 2018;171(2):359-69. PMID: 29846847

Axelsson U, Ryden L, Johnsson P, Eden P, Mansson J, Hallberg IR, et al. A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study. *BMC Cancer*. 2018;18(1):789. PMID: 30081937

Borgquist S, Rosendahl AH, Czene K, Bhoo-Pathy N, Dorkhan M, Hall P, Brand JS. Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study. *Breast Cancer Res*. 2018 Aug 9;20(1):93. doi: 10.1186/s13058-018-1026-7. PMID: 30092829

Bower H, Andersson TM, Crowther MJ, Dickman PW, Lambe M, Lambert PC. Adjusting Expected Mortality Rates Using Information From a Control Population: An Example Using Socioeconomic Status. *Am J Epidemiol*. 2018 Apr 1;187(4):828-836. doi: 10.1093/aje/kwx303. PMID: 29020167

Bremer T, Whitworth PW, Patel R, Savala J, Barry T, Lyle S, et al. A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk. *Clinical cancer research: an official journal of the American Association for Cancer Research*. 2018;24(23):5895-901. PMID: 30054280

Bruelker C, Vallon-Christersson J, Grabau† D, Ehinger A, Häkkinen J, Hegardt C, et al. Clinical Value of RNA Sequencing-Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative. *JCO Precis Oncol* 2018 Mar 9;2:PO.17.00135. PMID: 32913985

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2018;19(1):127-38. PMID: 29158011

Colombo M, Lòpez-Perolio I, Meeks HD, Caleca L, Parsons M, Li H, De Vecchi G, Tudini E, Foglia C, Mondini P, et al. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. *Hum Mutat.* 2018 Feb 20. doi: 10.1002/humu.23411. PMID: 29460995

Delcoigne B, Hagenbuch N, Schelin ME, Salim A, Lindstrom LS, Bergh J, et al. Feasibility of reusing time-matched controls in an overlapping cohort. *Statistical methods in medical research.* 2018;27(6):1818-29. PMID: 27659169

Eriksson L, Bergh J, Humphreys K, Warnberg F, Tornberg S, Czene K. Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study. *Int J Cancer* 2018;143(5):1093-104. PMID: 29603736

Eriksson M, Li J, Leifland K, Czene K, Hall P. A comprehensive tool for measuring mammographic density changes over time. *Breast Cancer Res Treat.* 2018 Feb 1. doi: 10.1007/s10549-018-4690-5. PMID: 29392583.

Fahlen M, Zhang H, Lofgren L, Masironi B, E VONS, BO VONS, et al. Expression of Progesterone and Androgen Receptors in the Breast of Premenopausal Women, Considering Menstrual Phase. *Anticancer research.* 2018;38(3):1499-510. PMID: 29491078

Falato C, Taylor SK, Szulkin R, Nordblom A, Eriksson L, Sofiadis A, Fredriksson I, Hartman J, Bergh J, Foukakis T. Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry. *Breast Cancer Res Treat.* 2018 Dec; 172(3):703-712. PMID:30225620

Foukakis T. Ribociclib in premenopausal women with advanced breast cancer. *Lancet Oncology* 2018; 19(7):850-852. PMID: 29804904

Foukakis T, Lovrot J, Matikas A, Zerdes I, Lorent J, Tobin N, et al. Immune gene expression and response to chemotherapy in advanced breast cancer. *Br J Ca* 2018;118(4):480- 8. PMID: 29370583

Frisk G, Ekberg S, Lidbrink E, et al. No association between low-dose aspirin use and breast cancer outcomes overall: a Swedish population-based study. *Breast Cancer Res.* 2018 Dec;20(1):142. PMID:30458873

Gabrielson M, Ubhayasekera K, Ek B, Andersson Franko M, Eriksson M, Czene K, Bergquist J, Hall P. Inclusion of Plasma Prolactin Levels in Current Risk Prediction Models of Premenopausal and Postmenopausal Breast Cancer. *JNCI Cancer Spectr.* 2018 Dec 4;2(4):pky055. doi: 10.1093/jncics/pky055. eCollection 2018 Oct. PMID: 31360875.

Johansson ALV, Andersson TM, Hsieh CC, Jirström K, Cnattingius S, Fredriksson I, Dickman PW, Lambe M. Tumor characteristics and prognosis in women with pregnancy-associated breast cancer. *Int J Cancer.* 2018 Apr 1;142(7):1343-1354. PMID:29168177

Karakatsanis A, Tasoulis MK, Warnberg F, Nilsson G, MacNeill F. Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer. *The British journal of surgery*. 2018;105(5):469-81. PMID: 29603132

Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. *Cell*. 2018;173(4):879-93.e13. PMID: 29681456

Li J, Ugalde-Morales E, Wen WX, Decker B, Eriksson M, Torstensson A, Christensen HN, Dunning AM, Allen J, Luccarini C, Pooley KA, Simard J, Dorling L, Easton DF, Teo SH, Hall P, Czene K. Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. *Cancer Res*. 2018 Nov 1;78(21):6329-6338. doi: 10.1158/0008-5472.CAN-18-1018. PMID: 30385609

Li J, Humphreys K, Ho PJ, Eriksson M, Darai-Ramqvist E, Lindström LS, Hall P, Czene K. Family History, Reproductive, and Lifestyle Risk Factors for Fibroadenoma and Breast Cancer. *JNCI Cancer Spectr*. 2018 Dec 10;2(3):pky051. doi: 10.1093/jncics/pky051. PMID: 31360866.

Ljungman L, Ahlgren J, Petersson LM, Flynn KE, Weinfurt K, Gorman JR, Wettergren L, Lampic C. Sexual dysfunction and reproductive concerns in young women with breast cancer: Type, prevalence, and predictors of problems. *Psychooncology*. 2018 Dec;27(12):2770-2777. doi: 10.1002/pon.4886. Epub 2018 Sep 27. PMID: 30203884

Lundgren C, Lindman H, Rolander B, Ekholm M. Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register. *Acta Oncol* 2018;1-6. PMID: 29493327

Majid S, Ryden L, Manjer J. Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients. *World journal of surgical oncology*. 2018;16(1):54. PMID: 29530065

Matikas A, Foukakis T, Bergh J. RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. *Journal of the National Cancer Institute*. 2018 Nov 1;110(11):1280-1281. doi: 10.1093/jnci/djy046. PMID: 29618043

Matikas A, Margolin S, Hellstrom M, Johansson H, Bengtsson NO, Karlsson L, et al. Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. *Breast Cancer Res Treat* 2018;168(2):349-55. PMID: 29190004

Nilsson MP, Törngren T, Henriksson K, Kristoffersson U, Kvist A, Silfverberg B, Borg Å, Loman N. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer. *Breast Cancer Res Treat* 2018 Feb;168(1):117-126. PMID: 29164420

Plate S, Emilsson L, Soderberg M, Brandberg Y, Warnberg F. High experienced continuity in breast cancer care is associated with high health related quality of life. *BMC Health Serv Res* 2018;18(1):127. PMID: 29458376

Plym A, Bower H, Fredriksson I, Holmberg L, Lambert PC, Lambe M. Loss in working years after a breast cancer diagnosis. *Br J Cancer* 2018;118(5):738-743. PMID: 29360816

Rodriguez-Wallberg KA, Eloranta S, Krawiec K, Lissmats A, Bergh J, Liljegren A. Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. *Breast Cancer Res Treat.* 2018 Feb;167(3):761-769. doi: 10.1007/s10549-017-4555-3. PMID: 29098528.

Rudolph A, Song M, Brook MN, Milne RL, Mavaddat N, Michailidou K, Bolla MK, Wang Q, Dennis J, Wilcox AN, et al. Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. *Int J Epidemiol.* 2018 Jan 5. doi: 10.1093/ije/dyx242. PMID: 29315403

Rydén L, Loman N, Larsson C, Hegardt C, Vallon-Christersson J, Malmberg M, et al. Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. *Br J Surg.* 2018;105(2):e158-e68. PMID: 29341157

Sjöstrom M, Staaf J, Eden P, Warnberg F, Bergh J, Malmstrom P, et al. Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. *Breast cancer research* 2018;20(1):64. PMID: 29973242

Strand F, Humphreys K, Holm J, Eriksson M, Törnberg S, Hall P, Azavedo E, Czene K. Long-term prognostic implications of risk factors associated with tumor size: a case study of women regularly attending screening. *Breast Cancer Res.* 2018 Apr 18;20(1):31. doi: 10.1186/s13058-018-0962-6. PMID: 29669579

Svee A, Mani M, Sandquist K, Audolfsson T, Folkvaljon Y, Isern AE, et al. Survival and risk of breast cancer recurrence after breast reconstruction with deep inferior epigastric perforator flap. *The British journal of surgery.* 2018;105(11):1446-53. PMID:29999520

Wadsten C, Wennstig AK, Garmo H, Nilsson G, Blomqvist C, Holmberg L, et al. Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. *Breast cancer research and treatment.* 2018;171(1):95-101. PMID: 29730730

Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu XO, Lu Y, Cai Q, et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nat Genet.* 2018 Jul;50(7):968-978. doi: 10.1038/s41588-018-0132-x. PMID: 29915430

Wulaningsih W, Garmo H, Ahlgren J, Holmberg L, Folkvaljon Y, Wigertz A, et al. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. *Breast cancer research and treatment.* 2018;172(1):167-77. PMID: 30030708

Yang H, He W, Eriksson M, Li J, Holowko N, Chiesa F, Hall P, Czene K. Inherited factors contribute to an inverse association between preeclampsia and breast cancer. *Breast Cancer Res.* 2018 Jan 23;20(1):6. doi: 10.1186/s13058-017-0930-6. PMID: 29361985

Zerdes I, Matikas A, Bergh J, Rassidakis GZ, Foukakis T. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. *Oncogene.* 2018. Aug;37(34):4639-4661. doi: 10.1038/s41388-018-0303-3. PMID: 29765155

2017

Abdoli G, Bottai M, Sandelin K, Moradi T. Breast cancer diagnosis and mortality by tumor stage and migration background in a nationwide cohort study in Sweden. *Breast* 2017;31:57-65. PMID: 27810701

Brand JS, Hedayati E, Bhoo-Pathy N, Bergh J, Hall P, Humphreys K, et al. Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study. *Cancer* 2017;123(3):468-475. PMID: 27727456

Dihge L, Bendahl PO, Rydén L. Nomograms for preoperative prediction of axillary nodal status in breast cancer. *Br J Surg* 2017 104(11):1494-1505. doi: 10.1002/bjs.10583. PMID: 28718896

Engqvist Boman L, Sandelin K, Wengstrom Y, Silen C. Patients' learning and understanding during their breast cancer trajectory. *Patient Educ Couns* 2017;100(5):795-804. PMID: 28043715

Foukakis T. Kemoterapi och målstyrda läkemedel kan förstärka varandra. 2017 Feb 14;114. pii: EEIS. Swedish: Läkartidningen; 2017.

Foukakis T, Bergh J. Prognostic and predictive factors in early, non-metastatic breast cancer. In: *UpToDate*, Basow, DS (Ed), UpToDate, Waltham, MA2017.

Fredholm H, Magnusson K, Lindstrom LS, Tobin NP, Lindman H, Bergh J, et al. Breast cancer in young women and prognosis: How important are proliferation markers? *Eur J Cancer* 2017;84:278-89. PMID: 28844016

Fredriksson I, Fredholm H. Sämre prognos för unga kvinnor med bröstcancer -Frågeställningar såsom fertilitet och graviditet viktigt att beakta. *Lakartidningen* 2017:114. PMID: 28221401.

Gao R, Kim C, Sei E, Foukakis T, Crosetto N, Chan LK, et al. Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. *Nat Commun* 2017;8(1):228. PMID: 28794488

Li J, Ivansson E, Klevebring D, Tobin NP, Lindstrom LS, Holm J, et al. Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. *Clin Cancer Res* 2017;23(10):2584-92. PMID: 27587435

Lundberg A, Lindstrom LS, Harrell JC, Falato C, Carlson JW, Wright PK, et al. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. *Clin Cancer Res* 2017;23(24):7512-7520. PMID: 28972043

Matikas A, Foukakis T, Bergh J. Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts. *Acta Oncol* 2017;56(9):1143-51. PMID: 28537808

Matikas A, Foukakis T, Bergh J. Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. *Crit Rev Oncol Hematol* 2017;114:91-101. PMID: 28477750

Matikas A, Foukakis T, Michalakis I, Georgoulas V. Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer. *Expert Rev Anticancer Ther* 2017;17(4):319-326. PMID: 28128984

Nakamura M, Zhang Y, Yang Y, Sonmez C, Zheng W, Huang G, et al. Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production. *Proc Natl Acad Sci U S A* 2017;114(45):E9635-E9644. PMID: 29078273

Palazon A, Tyrakis PA, Macias D, Velica P, Rundqvist H, Fitzpatrick S, et al. An HIF-1alpha/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. *Cancer Cell* 2017;32(5):669-83.e5. PMID: 29136509

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. *N Engl J Med*. 2017 Nov 9;377(19):1836-1846. doi:10.1056/NEJMoa1701830. PMID: 29117498

Persson H, Søkilde R, Häkkinen J, Pirona AC, Vallon-Christersson J, Kvist A, Mertens F, Borg Å, Mitelman F, Höglund M, Rovira C. Frequent miRNA-convergent fusion gene events in breast cancer. *Nat Commun*. 2017 Oct 5;8(1):788. PMID: 28983113

Robertson S, Adolfsson J, Stattin P, Sjøvall A, Wingersjö R, Hanning M, et al. Waiting times for cancer patients in Sweden: A nationwide population-based study. *Scand J Public Health* 2017;45(3):230-237. PMID: 28443490

Strand F, Humphreys K, Eriksson M, Li J, Andersson TM, Tornberg S, et al. Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer. *Int J Cancer* 2017;140(1):34-40. PMID: 27615710

Tobin NP, Lundberg A, Lindstrom LS, Harrell JC, Foukakis T, Carlsson L, et al. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. *Clin Cancer Res* 2017;23(23):7225-7231. PMID: 28972041

Ventura F, Sawatzky R, Ohlen J, Karlsson P, Koinberg I. Challenges of evaluating a computer-based educational programme for women diagnosed with early-stage breast cancer: a randomised controlled trial. *Eur J Cancer Care* 2017;26(5). PMID: 27339805

Wadsten C, Garmo H, Fredriksson I, Sund M, Wärnberg F. Risk of death from breast cancer after treatment for ductal carcinoma in situ. *Br J Surg* 2017 Oct;104(11):1506-1513. PMID:28832961

Yang H, Brand JS, Fang F, Chiesa F, Johansson AL, Hall P, et al. Time-dependent risk of depression, anxiety, and stress-related disorders in patients with invasive and in situ breast cancer. *Int J Cancer* 2017;140(4):841-52. PMID: 27859142

Bondesson T, Petersson LM, Wennman-Larsen A, Alexanderson K, Kjeldgard L, Nilsson MI. A study to examine the influence of health professionals' advice and support on work capacity and sick leave after breast cancer surgery. *Support Care Cancer* 2016;24(10):4141-8. PMID: 27146389

Brand JS, Colzani E, Johansson ALV, Giesecke J, Clements M, Bergh J, et al. Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis. *Journal Infect* 2016;72(6):650-658. PMID: 27063280

Brand JS, Hedayati E, Humphreys K, Ludvigsson JF, Johansson AL, Bergh J, Hall P, Czene K. Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients. *Clin Cancer Res*. 2016 Nov 1;22(21):5249-5255. doi: 10.1158/1078-0432.CCR-16-1110. PMID: 27803117

Colzani E, Clements M, Johansson AL, Liljegren A, He W, Brand J, et al. Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. *Br J Cancer* 2016;115(11):1400-1407. PMID: 27701383

Crowther MJ, Andersson TM, Lambert PC, Abrams KR, Humphreys K. Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification. *Stat Med* 2016;35(7):1193-209. PMID: 26514596

Dihge L, Grabau DA, Rasmussen RW, Bendahl PO, Ryden L. The accuracy of preoperative axillary nodal staging in primary breast cancer by ultrasound is modified by nodal metastatic load and tumor biology. *Acta Oncol* 2016;55(8):976-82. PMID: 27050668

Falato C, Tobin NP, Lorent J, Lindstrom LS, Bergh J, Foukakis T. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. *Mol Oncol* 2016;10(4):517-25. PMID: 26651914

Foukakis T, Falato C, Bergh J. A 21-Gene Expression Assay in Breast Cancer. *The New England journal of medicine*. 2016;374(14):1386-7.

Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, et al. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. *JAMA* 2016;316(18):1888-1896. PMID: 27825007

Fredholm H, Magnusson K, Lindstrom LS, Garmo H, Falt SE, Lindman H, et al. Long-term outcome in young women with breast cancer: a population-based study. *Breast Cancer Res Treat* 2016;160(1):131-143. PMID: 27624330

Frisell A, Lagergren J, de Boniface J. National study of the impact of patient information and involvement in decision-making on immediate breast reconstruction rates. *Br J Surg* 2016;103(12):1640-1648. PMID: 27550796

Gabrielson M, Chiesa F, Paulsson J, Strell C, Behmer C, Ronnow K, et al. Amount of stroma is associated with mammographic density and stromal expression of oestrogen receptor in normal breast tissues. *Breast Cancer Res Treat* 2016;158(2):253-61. PMID: 27349429

Gondos A, Jansen L, Heil J, Schneeweiss A, Voogd AC, Frisell J, et al. Time trends in axilla management among early breast cancer patients: Persisting major variation in clinical practice across European centers. *Acta Oncol* 2016;55(6):712-9. PMID: 26878397

Hilborn E, Gacic J, Fornander T, Nordenskjold B, Stal O, Jansson A. Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-alpha-negative breast cancer. *Br J Cancer* 2016;114(3):248-55. PMID: 26742006

Li J, Eriksson M, Czene K, Hall P, Rodriguez-Wallberg KA. Common diseases as determinants of menopausal age. *Hum Reprod* 2016;31(12):2856-2864. PMID: 27798047

Li J, Holm J, Bergh J, Eriksson M, Darabi H, Lindstrom LS, et al. Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers. *Ann Oncol* 2016;27(6):1181. PMID: 26945009

Li J, Humphreys K, Eriksson M, Dar H, Brandberg Y, Hall P, et al. Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: A cross-sectional study. *Int J Cancer* 2016;139(11):2415-25. PMID: 27486698

Lindblad C, Sandelin K, Petersson LM, Rohani C, Langius-Eklöf A. Stability of the 13-item sense of coherence (SOC) scale: a longitudinal prospective study in women treated for breast cancer. *Qual Life Res* 2016;25(3):753-60. PMID: 26319753

Lu Y, Segelman J, Nordgren A, Lindstrom L, Frisell J, Martling A. Increased risk of colorectal cancer in patients diagnosed with breast cancer in women. *Cancer Epidemiol* 2016;41:57-62. PMID: 26826682

Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, et al. ERalpha Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer. *Clin Cancer Res* 2016;22(6):1421-31. PMID: 26542058

Nilsson MI, Saboonchi F, Alexanderson K, Olsson M, Wennman-Larsen A, Petersson LM. Changes in importance of work and vocational satisfaction during the 2 years after breast cancer surgery and factors associated with this. *J Cancer Surviv* 2016;10(3):564-72. PMID: 26644189

Nordenskjöld A, Fohlin H, Fornander T, Lofdahl B, Skoog L, Stal O. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer. *Breast Cancer Res Treat* 2016;160(2):313-22. PMID: 27722840

Papakonstantinou A, Foukakis T, Rodriguez-Wallberg KA, Bergh J. Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer? *J Clin Oncol* 2016;34(14):1573-9. PMID: 26951320

Strand F, Humphreys K, Cheddad A, Tornberg S, Azavedo E, Shepherd J, et al. Novel mammographic image features differentiate between interval and screen-detected breast cancer: a case-case study. *Breast Cancer Res* 2016;18(1):100. PMID: 27716311

Tobin NP, Wennmalm K, Lindstrom LS, Foukakis T, He L, Genove G, et al. An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors. *Clin Cancer Res* 2016;22(10):2417-26. PMID: 26769751

Wadsten C, Heyman H, Holmqvist M, Ahlgren J, Lambe M, Sund M, et al. A validation of DCIS registration in a population-based breast cancer quality register and a study of treatment and prognosis for DCIS during 20 years. *Acta Oncol* 2016;55(11):1338-43. PMID: 27548561

Valachis A, Garmo H, Weinman J, Fredriksson I, Ahlgren J, Sund M, et al. Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study. *Breast Cancer Res Treat* 2016;159(2):293-303. PMID: 27492739

Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T. Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes. *Oncotarget*. 2016;7(46):74966-74978. PMID: 27589561

Veenstra C, Perez-Tenorio G, Stelling A, Karlsson E, Mirwani SM, Nordenskoljd B, et al. Met and its ligand HGF are associated with clinical outcome in breast cancer. *Oncotarget* 2016;7(24):37145-37159. PMID: 27175600

Wennman-Larsen A, Nilsson MI, Saboonchi F, Olsson M, Alexanderson K, Fornander T, et al. Can breast cancer register data on recommended adjuvant treatment be used as a proxy for actually given treatment? *Eur J Oncology Nurs* 2016;22:1-7. PMID: 27179887

Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. *Ann Oncol* 2016;27(8):1532-8. PMID: 27194814

2015

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet* 2015;386(10001):1353-61. PMID: 26211824

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet* 2015;386(10001):1341-52. PMID: 26211827

Bostner J, Karlsson E, Eding CB, Perez-Tenorio G, Franzen H, Konstantinell A, et al. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts. *Endocr Relat Cancer* 2015;22(3):331-43. PMID: 25972244

Ekholm M, Grabau D, Bendahl PO, Bergh J, Elmberger G, Olsson H, et al. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment. *Acta Oncol* 2015;54(7):1040-8. PMID: 25959664

Foukakis T, Lovrot J, Sandqvist P, Xie H, Lindstrom LS, Giorgetti C, et al. Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. *Mol Oncol* 2015;9(7):1384-91. PMID: 25888067

Göthlin Eremo A, Tina E, Wegman P, Stal O, Fransen K, Fornander T, et al. HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen. *Int J Oncol* 2015;47(4):1311-20. PMID: 26238412

He W, Fang F, Varnum C, Eriksson M, Hall P, Czene K. Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer. *J Clin Oncol* 2015;33(20):2262-9. PMID: 26033800

Holm J, Humphreys K, Li J, Ploner A, Cheddad A, Eriksson M, et al. Risk factors and tumor characteristics of interval cancers by mammographic density. *J Clin Oncol* 2015;33(9):1030-7. PMID: 25646195

Johansson HJ, Sanchez BC, Forshed J, Stal O, Fohlin H, Lewensohn R, et al. Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. *Clin Proteomics*. 2015;12(1):8. PMID: 25878567

Karlsson E, Veenstra C, Emin S, Dutta C, Perez-Tenorio G, Nordenskjold B, et al. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer. *Breast Cancer Res Treat* 2015;153(1):31-40. PMID: 26208487

Kessler L, Falato C, Margolin S, Bergh J, Foukakis T. A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. *Acta Oncol* 2015;54(4):522-9. PMID: 25383448

Kimbung S, Kovacs A, Danielsson A, Bendahl PO, Lovgren K, Frostvik Stolt M, et al. Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. *Oncotarget* 2015;6(32):33306-18. PMID: 26375671

Klevebring D, Lindberg J, Rockberg J, Hilliges C, Hall P, Sandberg M, et al. Exome sequencing of contralateral breast cancer identifies metastatic disease. *Breast Cancer Res Treat* 2015;151(2):319-24. PMID: 25922084

Li Y, Roswall N, Sandin S, Strom P, Adami HO, Weiderpass E. Adherence to a healthy Nordic food index and breast cancer risk: results from a Swedish cohort study. *Cancer Causes Control* 2015;26(6):893-902. PMID: 25783459

Saal LH, Vallon-Christersson J, Hakkinen J, Hegardt C, Grabau D, Winter C, et al. The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. *Genome Med* 2015;7(1):20. PMID: 25722745

Sackey H, Johansson H, Sandelin K, Liljegren G, MacLean G, Frisell J, et al. Self-perceived, but not objective lymphoedema is associated with decreased long-term health-related quality of life after breast cancer surgery. *Eur J Surg Oncol* 2015;41(4):577- 84. PMID: 25659877

Schoormans D, Czene K, Hall P, Brandberg Y. The impact of co-morbidity on health-related quality of life in breast cancer survivors and controls. *Acta Oncol* 2015;54(5):727-34. PMID: 25761088

Söderlund Leifler K, Askid A, Fornander T, Stenmark Askmalm M. The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer. *J Cancer Res Clin Oncol* 2015;141(5):797-804. PMID: 25354554

Tobin NP, Foukakis T, De Petris L, Bergh J. The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. *Journal of internal medicine* 2015;278(6):545-70. PMID: 26373821

Tobin NP, Harrell JC, Lovrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. *Ann Oncol* 2015;26(1):81-8. PMID: 25361981

van der Leij F, Bosma SC, van de Vijver MJ, Wesseling J, Vreeswijk S, Rivera S, et al. First results of the preoperative accelerated partial breast irradiation (PAPBI) trial. *Radiother Oncol* 2015;114(3):322-7. PMID: 25701298

2014

Adam H, Bygdeson M, de Boniface J. The oncological safety of nipple-sparing mastectomy - a Swedish matched cohort study. *Eur J Surg Oncol* 2014;40(10):1209-15. PMID: 25186915

Colzani E, Johansson AL, Liljegren A, Foukakis T, Clements M, Adolfsson J, et al. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. *Br J Ca* 2014;110(5):1378-84. PMID: 24434426

Enlund M, Berglund A, Andreasson K, Cicek C, Enlund A, Bergkvist L. The choice of anaesthetic--sevoflurane or propofol--and outcome from cancer surgery: a retrospective analysis. *Ups J Med Sci.* 2014 Aug;119(3):251-61. doi: 10.3109/03009734.2014.922649. PMID: 24857018.

Falato C, Lorent J, Tani E, Karlsson E, Wright PK, Bergh J, et al. Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. *Breast Cancer Res Treat* 2014;147(2):407-14. PMID: 25129344

Gonzalez V, Sandelin K, Karlsson A, Aberg W, Lofgren L, Iliescu G, et al. Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. *World J Surgery* 2014;38(7):1685-93. PMID: 24817517

Hajiebrahimi M, Cnattingius S, Lambe M, Hsieh CC, Ahlgren J, Adolfsson J, et al. Birth size in the most recent pregnancy and maternal mortality in premenopausal breast cancer by tumor characteristics. *Breast Cancer Res Treat* 2014;145(2):471-80. PMID: 24744092

Hilborn E, Sivik T, Fornander T, Stal O, Nordenskjold B, Jansson A. C-X-C ligand 10 and C-X-C receptor 3 status can predict tamoxifen treatment response in breast cancer patients. *Breast Cancer Res Treat* 2014;145(1):73-82. PMID: 24715380

Karlsson E, Appelgren J, Solterbeck A, Bergenheim M, Alvariza V, Bergh J. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology. *Eur J Cancer* 2014;50(17):2916-24.

Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirstrom K, Bergh J, et al. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. *Eur J Ca* 2014;50(3):517-24. PMID: 25241230

Liljegren A, Unukovych D, Gagliardi G, Bjohle J, Wickman M, Johansson H, et al. No difference in dose distribution in organs at risk in postmastectomy radiotherapy with or without breast implant reconstruction. *Radiat Oncol* 2014;9:14. PMID: 24406085

Lundh MH, Lampic C, Nordin K, Ahlgren J, Bergkvist L, Lambe M, et al. Sickness absence and disability pension following breast cancer - A population-based matched cohort study. *Breast* 2014;23(6):844-51. PMID: 25305791

McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet* 2014;383(9935):2127-35. PMID: 24656685

Sackey H, Magnuson A, Sandelin K, Liljegren G, Bergkvist L, Fulep Z, et al. Arm lymphoedema after axillary surgery in women with invasive breast cancer. *Brit J Surg* 2014;101(4):390-7. PMID: 24536010

Sjöstrom M, Hartman L, Grabau D, Fornander T, Malmstrom P, Nordenskjöld B, et al. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer. *Breast Cancer Res Treat* 2014;145(1):61-71. PMID: 24715381

Stålhammar G, Rosin G, Fredriksson I, Bergh J, Hartman J. Low concordance of biomarkers in histopathological and cytological material from breast cancer. *Histopathology* 2014;64(7):971-80. PMID: 24320941

Wärnberg F, Garmo H, Emdin S, Hedberg V, Adwall L, Sandelin K, et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. *J Clin Oncol* 2014;32(32):3613-8. PMID: 25311220

von Stedingk H, Xie H, Hatschek T, Foukakis T, Ryden A, Bergh J, et al. Validation of a novel procedure for quantification of the formation of phosphoramidate mustard by individuals treated with cyclophosphamide. *Cancer Chemother Pharmacol* 2014;74(3):549-58. PMID: 25053385

Zetterlund L, Stemme S, Arnrup H, de Boniface J. Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ. *The Br J Surg* 2014;101(5):488-94. PMID: 24493058

2013

Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L. Causes of false-negative sentinel node biopsy in patients with breast cancer. *Br J Surg* 2013;100(6):775-83. PMID: 23436699

Couto E, Sandin S, Lof M, Ursin G, Adami HO, Weiderpass E. Mediterranean dietary pattern and risk of breast cancer. *PloS One* 2013;8(2): e55374. PMID: 23390532

Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med* 2013;368(11):987-98. PMID: 23484825

Hajiebrahimi MH, Bahmanyar S, Lambe M, Adolfsson J, Fornander T, Warnberg F, et al. Placental weight and mortality in premenopausal breast cancer by tumor characteristics. *Breast Cancer Res Treat* 2013;137(1):297-305. PMID: 23149466

Holmberg L, Wong YN, Tabar L, Ringberg A, Karlsson P, Arnesson LG, et al. Mammography casting-type calcification and risk of local recurrence in DCIS: analyses from a randomised study. *Br J Cancer* 2013;108(4):812-9. PMID: 23370209

Lundh MH, Lampic C, Nordin K, Ahlgren J, Bergkvist L, Lambe M, et al. Changes in health-related quality of life by occupational status among women diagnosed with breast cancer--a population-based cohort study. *Psychooncology* 2013;22(10):2321-31. PMID: 23585294

Milosevic J, Klinge J, Borg AL, Foukakis T, Bergh J, Tobin NP. Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. *BMC Cancer* 2013; 13: 473. PMID: 24119434

Nilsson MI, Petersson LM, Wennman-Larsen A, Olsson M, Vaez M, Alexanderson K. Adjustment and social support at work early after breast cancer surgery and its associations with sickness absence. *Psychooncology* 2013;22(12):2755-62. PMID: 23824596

Sandberg ME, Alkner S, Hartman M, Eloranta S, Ryden L, Ploner A, et al. Influence of radiotherapy for the first tumor on aggressiveness of contralateral breast cancer. *Int J Cancer* 2013;132(10):2388-94. PMID: 23034813

Walters S, Maringe C, Butler J, Rachet B, Barrett-Lee P, Bergh J, et al. Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study. *Br J Cancer* 2013;108(5):1195-208.

Wennman-Larsen A, Alexanderson K, Olsson M, Nilsson MI, Petersson LM. Sickness absence in relation to breast and arm symptoms shortly after breast cancer surgery. *Breast* 2013;22(5):767-72. PMID: 23411122

Wennman-Larsen A, Olsson M, Alexanderson K, Nilsson MI, Petersson LM. Arm morbidity and sick leave among working women shortly after breast cancer surgery. *Eur J Oncol Nurs* 2013;17(1):101-6. PMID: 22705269

Wilson AR, Marotti L, Bianchi S, Biganzoli L, Claassen S, Decker T, et al. The requirements of a specialist Breast Centre. *Eur J Cancer* 2013;49(17):3579- 87. PMID: 23968730

Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. *Clin Cancer Res* 2013;19(15):4196-205. PMID: 23757354

Andersson Y, Frisell J, de Boniface J, Bergkvist L. Prediction of non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastases: evaluation of the tenon score. *Breast Cancer* 2012;6:31-8. PMID: 22346360

Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, Warnberg F, et al. Impact of comorbidity on management and mortality in women diagnosed with breast cancer. *Breast Cancer Res Treat* 2012;135(1):281-9. PMID: 22829398

Foukakis T, Astrom G, Lindstrom L, Hatschek T, Bergh J. When to order a biopsy to characterise a metastatic relapse in breast cancer. *Ann Oncol* 2012;23 Suppl 10:x349-53. PMID: 22987990

Hoyer M, Nordin K, Ahlgren J, Bergkvist L, Lambe M, Johansson B, et al. Change in working time in a population-based cohort of patients with breast cancer. *J Clin Oncol* 2012;30(23):2853-60. PMID: 22778312

Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. *JAMA* 2012;308(2):147-56. PMID: 22782416

Sandberg ME, Hall P, Hartman M, Johansson AL, Eloranta S, Ploner A, et al. Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study. *PloS One* 2012;7(10):e46535. PMID: 23056335

Sandberg ME, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P, et al. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. *Breast Ca Res Treat* 2012;134(2):793-800. PMID: 22622811

2011

Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. *Lancet* 2011;377(9760):127-38. PMID: 21283212

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. *Lancet* 2011; 378(9804):1707-16. PMID: 2219144.

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Relevance of breast cancer hormone receptor and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. *Lancet* 2011;378(9793):771-84. PMID: 21802721

Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J, Bergh J. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. *Breast Cancer Res Treat* 2011;130(2):553-60. PMID: 21617918

McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson NO, Bennet AM, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. *Radiother Oncol* 2011;100(2):167-75. PMID: 21752480

Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M, Fjallskog ML. Similarities and differences in the characteristics and primary treatment of breast cancer in men and women - a population based study (Sweden). *Acta Oncol* 2011;50(7):1083-8. PMID: 21830994

Norenstedt S, Granath F, Ekbom A, Bergh J, Lambe M, Adolfsson J, et al. Breast cancer associated with primary hyperparathyroidism: a nested case control study. *Clin Epidemiol* 2011;3:103-6. PMID: 21487450

Vu H, Tani E, Johansson H, Adolfsson J, Krawiec K, Van TT, et al. Difference in hormone receptor content in breast cancers from Vietnamese and Swedish women. *Acta Oncol* 2011;50(3):353-9. PMID: 21395466

Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. *Breast Cancer Res Treat* 2011;125(2):553-61. PMID: 20628810

2010

Lambe M, Wigertz A, Holmqvist M, Adolfsson J, Bardage C, Fornander T, et al. Reductions in use of hormone replacement therapy: effects on Swedish breast cancer incidence trends only seen after several years. *Breast Cancer Res Treat* 2010;121(3):679-83. PMID: 19894110

2009

Eaker S, Halmin M, Bellocco R, Bergkvist L, Ahlgren J, Holmberg L, et al. Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). *Int J Cancer* 2009;124(1):180-7. PMID: 18844231

Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. *PloS one*. 2009;4(11):e7695. PMID: 19907646

Hackshaw A, Baum M, Fornander T, Nordenskjold B, Nicolucci A, Monson K, et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. *J Natl Cancer Inst* 2009;101(5):341-9. PMID: 19244174

Holmberg L, Adolfsson J, Mucci L, Garmo H, Adami HO, Moller H, et al. Season of diagnosis and prognosis in breast and prostate cancer. *Cancer Causes Control* 2009;20(5):663-70. PMID: 19067189

Koinberg I, Engholm GB, Genell A, Holmberg L. A health economic evaluation of follow-up after breast cancer surgery: results of an rct study. *Acta Oncol* 2009;48(1):99-104. PMID: 18766474

Koscielny S, Arriagada R, Adolfsson J, Fornander T, Bergh J. Impact of tumour size on axillary involvement and distant dissemination in breast cancer. *Br J Cancer* 2009;101(6):902-7. PMID: 19690546

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, et al. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. *Med* 2009;26(4):480-90. PMID: 19130322

Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtio J, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. *Ann Oncol* 2009;20(10):1639-46. PMID: 19549711

Tan BK, Lim GH, Czene K, Hall P, Chia KS. Do Asian breast cancer patients have poorer survival than their western counterparts? A comparison between Singapore and Stockholm. *Breast Cancer Res* 2009;11(1):R4. PMID: 19166618